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Introduction 
 
1  INTRODUCTION 
All organisms are constantly and unavoidably exposed to foreign chemicals, so called xenobiotics, 
which include both synthetic and natural chemicals such as drugs, industrial chemicals, pesticides, and 
pollutants, pyrolysis products in cooked food, alkaloids, secondary plant metabolites, and toxins 
produced by molds, plants and animals. The physical property that enables many xenobiotics to be 
absorbed through the skin, lungs, or gastrointestinal tract, namely their lipophilicity, is an obstacle to 
their elimination because lipophilic compounds can either not be excreted via the bile or the kidney at 
all, or would be readily reabsorbed from the gut or the renal tubuli. Consequently, the elimination of 
xenobiotics often depends on their conversion to more water-soluble compounds by a process known 
as biotransformation, which is catalyzed by drug metabolizing enzymes (DMEs) in the liver and other 
tissues. 
 
1.1  Drug Metabolizing Enzymes (DME) 
Reactions catalyzed by DMEs are often divided into “Phase I” and “Phase II” (Table 1). Phase I 
DMEs, many of which are cytochromes P450, sometimes participate in detoxification of reactive 
substrates. In addition, they are often involved in the activation of inert protoxicants, promutagens and 
procarcinogens to electrophilic intermediates that can bind as adducts to proteins or DNA and/or cause 
oxidative stress (Dalton et al., 1999; Kidd et al., 1999; Nebert, 2000). Phase II DMEs (e.g. 
methyltransferases, UDP glucoronosyltransferases, glutathione transferases, sulfotransferases) are 
sometimes involved in metabolic activation (Nebert et al., 1996), but they usually conjugate various 
Phase I products and other reactive intermediates to form water-soluble derivatives, completing the 
detoxification cycle. Therefore, it seems likely, that genetic differences in the regulated expression of 
activity level of Phase I and Phase II DME genes might be crucial factors in defining susceptibility to 
toxicity or cancer caused by drugs and other environmental pollutants. Hundreds of genes coding for 
drug metabolizing enzymes exist in the human genome. Polymorphism in several such genes causing 
high levels of one enzyme and low levels of another enzyme in a specific pathway involved in the 
1 
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metabolism of a particular environmental pollutant could lead to 30- or more than 40-fold differences 
between two individuals in response to that foreign chemical (Nebert, 2000). 
 
Table 1*. Phase I and phase II DMEs  
Enzyme class Reaction type Enzymes 
Phase I DMEs
Hydroxylation, N- and O-
dealkylation, desamination,  
oxidative dehalogenation 
Cytochrome P450-monooxygenase 
N- and S-Oxidation Cytochrome P450-monooxigenases, 
flavinmonooxigenases 
Dehydration Alcohol dehydrogenases 
Oxidation 
 
Dehydration of amines Monoaminoxidases 
Dehalogenation of nitro groups Cytochrome P450-monooxigenases Reduction 
 Carbonyl reduction Carbonylreductases 
Hydrolysis of epoxides Epoxide Hydrolases 
Hydrolysis of esters Carboxylesterases 
Hydrolysis 
Hydrolysis of peptides Peptidases 
Oxidation of superoxide anions Superoxide dismutases Others 
 Peroxidation Glutathione peroxidases 
Phase II DMEs
Conjugation Glucuronosylation UDP-glucuronosyltransferases 
 Sulfation Sulfotransferases 
 Acetylation O- and N-acetyltransferases 
 Methylation O-, N- and S-methyltransferases 
 Glutathione S-conjugation Glutathione S-transferases 
*Adapted from Elke Störmer, Dissertation, Berlin, 2001.  
 
1.2 Cytochrome P450 Enzymes 
1.2.1  Discovery 
The recognition of the existence of cytochrome P450 hemoproteins dates back to the late 1950s, when 
a carbon-monoxide-binding protein pigment was reported to be present in the endoplasmic reticulum 
of the liver (Garfinkel, 1958; Klingenberg, 1958), and to the later identification of the pigment as b-
type cytochrome (Omura and Sato, 1962; Omura and Sato, 1964a; Omura and Sato, 1964b). 
Shortly thereafter, the ability of cytochrome P450 to serve as terminal oxidase in the metabolism of 
steroid hormones (Estabrook et al., 1963) and xenobiotics (Cooper et al., 1965) was demonstrated. 
These observations were quickly followed by the recognition that multiple forms of cytochrome P450 
exit in the fragments of endoplasmic reticulum, the microsomes (Lu et al., 1971; Guengerich et al., 
1982a; Guengerich et al., 1982b; Guengerich et al., 1982c). 
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1.2.2 Function 
All cytochrome P450 enzymes are heme-containing proteins. The heme iron in cytochrome P450 is 
usually in the ferric (Fe ) state. When reduced to the ferrous (Fe ) state, cytochrome P450 can bind 
ligands such as O  and carbon monoxide (CO). The basis reaction catalyzed by cytochrome P450 is 
monooxygenation in which one atom of oxygen is incorporated into a substrate (RH); the other one is 
reduced to water with reducing equivalents derived from NADPH: 
3+ 2+
2
O  + 2e  + RH + 2H  → H O + ROH 2 - + 2
 
 
 
Fig. 1 Catalytic cycle of cytochrome P450 enzymes (adapted from Guengerich and Macdonald 
(Guengerich and MacDonald, 1990))
 
The catalytic cycle represented in the above picture may be summarized as follows: (1) The binding of 
a substrate to a P450 causes a lowering of the redox potential (Ruckpaul et al., 1985), which makes the 
transfer of an electron favorable from its redox partner, NADH or NADPH. This is accompanied by a 
change in the spin state of the hem iron at the active site. (2) The next stage in the cycle is the 
reduction of the Fe3+ ion by an electron transferred from NAD(P)H via an electron transfer chain that 
depends on a single specific NADPH P450 reductase that contains both FAD and FMN as cofactors 
(Coon et al., 1975). FAD can accept electrons from NADPH and FMN functions as the single electron 
carrier. (3) An O2 molecule binds rapidly to the Fe2+ ion forming Fe2+ + O2. There is evidence to 
suggest that this complex then undergoes a slow conversion to a more stable complex Fe3+ - O2- 
(Archakov et al., 1990). (4) A second reduction is required by the stoichiometry of the reaction. This 
 3
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has been determined to be the rate-determining step of the reaction (Imai et al., 1977). A comparison 
between the bond energies of O2, O2-, and O22- suggest that the Fe3+ - O22- complex is the most 
favorable starting point for the next stage of the reaction to occur (Levis, 1996). Some microsomal 
P450s systems may receive the second electron from NADPH through cytochrome b5; however the 
mechanism of this interaction still remains speculative (Schenkman and Jansson, 2003).(5) The O22- 
reacts with two protons from the surrounding solvent, breaking the O-O bound, forming water and 
leaving an (Fe – O)3+ complex. (6) The Fe-ligated oxygen atom (O) is transferred to the substrate 
forming an hydroxylated form of the substrate. (7) The product is released from the active site of the 
enzyme which returns to its initial state. 
 
1.2.3 Evolution 
Several suggestions concerning P450 evolution can be made based on the examination of the 
phylogenetic tree and its correlation with catalytic activities of cytochrome P450s. The earliest P450s 
are those that now metabolize steroids and fatty acids. The fatty acid-metabolizing P450 IV family and 
the steroid-inducible P450 III genes diverged more than 1 billion years ago. The P450 I and P450 II 
gene families formed about 800 million years ago and these genes are now responsible for the 
metabolism of drugs and carcinogens (Nelson and Strobel, 1987).  
 
1.2.4 Classification 
The highest concentration of P450 enzymes involved in xenobiotic biotransformation is found in the 
endoplasmatic reticulum (microsomes) of the liver, but P450 enzymes are expressed in almost all 
tissues. The human microsomal P450 enzymes involved in xenobiotic biotransformation belong to 
three main P450 gene families, namely CYP1, CYP2 and CYP3. Liver microsomes also contain P450 
enzymes encoded by the CYP4 gene family, the substrates of which include several fatty acids and 
eicosanoids but relatively few xenobiotics. A classification of all existing 57 human P450s based on 
substrate class is given in Table 2. 
 
Table 2*. Classification of human P450s based on major substrate class  
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CYP Family Steroids Xenobiotics Fatty acids Eicosanoids Vitamins Unknown 
1 1A1 
1A2 
1B1 
 
1A1 
1A2 
1B1 
1A1 
1B1 
1A2 
 
1A1 
1A2 
1B1 
 
2 2A6 
2B6 
2C18 
2C19 
2D6 
2E1 
2J2 
2A6 
2A13 
2B6 
2C8 
2C9 
2C18 
2C19 
2D6 
2E1 
2F1 
2J2 
2A6 
2B6 
2C19 
2D6 
2E1 
2J2 
2B6 
2C8 
2C9 
2E1 
2J2 
2A6 
2B6 
2C19 
2D6 
2E1 
 
2A7 
2R1 
2S1 
2U1 
2W1 
3 3A4 
3A5 
3A7 
3A43 
3A4 
3A5 
3A7 
 
3A4 
3A5 
 
3A4 
 
3A4 
3A5 
3A7 
 
3A43 
4 4B1 
 
4B1 
4F12 
4A11 
4B1 
4F2 
4F3 
4F8 
4F12 
4A11 
4F2 
4F3 
4F8 
4F12 
 4A22 
4F11 
4F22 
4V2 
4X1 
4Z1 
5  5A1  5A1   
7 7A1 
7B1 
     
8 8A1 
8B1 
8A1  8A1   
11 11A1 
11B1 
11B2 
11A1 
11B1 
11B2 
  11B1 
 
 
Others 17 
19 
21A2 
27A1 
39A1 
46A1 
51 
17 
19 
21A2 
26A1 
51 
  19 
24 
26A1 
26B1 
27A1 
27B1 
20 
26C1 
27C1 
(*Adapted from Guengerich FP (Guengerich, 2004))  
 
1.2.5 Interindividual variability 
The expression and activity of each P450 enzyme have been shown to vary from one individual to the 
other, due to environmental and genetic factors (Meyer, 1994; Shimada et al., 1994). Decreased P450 
activity can result from (1) a genetic mutation that either blocks the synthesis of a P450 enzyme or 
leads to the synthesis of a catalytically compromised or inactive enzyme, (2) exposure to an 
environmental factor (such as an infectious disease or a xenobiotic) that down-regulates P450 enzyme 
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expression, or (3) exposure to a xenobiotic that inhibits or inactivates a pre-existing P450 enzyme. By 
inhibiting cytochrome P450, one drug can impair the biotransformation of another drug. Such drug-
drug interactions can lead to an excessive pharmacological or toxicological response to the second 
drug. In this regard, inhibition of cytochrome P450 mimics the effects of a genetic deficiency in P450 
enzyme expression. Increased P450 enzyme activity can result from (1) gene duplication leading to 
overexpression of a P450 enzyme, (2) exposure to environmental factors, such as xenobiotics, that 
induce the synthesis of cytochrome P450, or (3) stimulation of a pre-existing enzyme by a xenobiotic. 
By inducing cytochrome P450 one drug can stimulate the metabolism of a second drug and thereby 
decrease or increase its therapeutic effect. A dramatic effect of this type of drug interaction is the 
induction of ethinylestradiol metabolism by phenobarbital and rifampin, which can decrease the 
contraceptive effect of the former drug and lead to pregnancy (Breckenridge et al., 1980). Similarly, a 
significant decrease (67%) in oral tacrolimus area under the concentration-time curve has been 
observed in healthy volunteers when co-administered with rifampin (CYP3A inducer) (Christians et 
al., 2002). Allelic variants, which arise by point mutations in the wild-type gene, are another source of 
interindividual variation in P450 activity. Amino acid substitution can increase or, more commonly, 
decrease P450 enzyme activity, although the effect may be substrate-dependent. Some of the genetic 
factors that influence P450 activity identified thus far are summarized ((Nagata and Yamazoe, 2002), 
http://www.imm.ki.se/CYPalleles). The environmental factors which are known to affect P450 
expression include medications (e.g. barbiturates, rifampin, isoniazid), food (e.g. cruciferous 
vegetables, charcoal-broiled beef), social habits (e.g. alcohol consumption, cigarette smoking), and 
disease status (diabetes, inflammation, hyperthyroidism and hypothyroidism). When environmental 
factors influence P450 enzyme levels, a considerable variation may be observed when xenobiotic 
biotransformation (e.g. drug metabolism) is measured repeatedly in the same individual. 
 
1.2.6 Clinical relevance of genetic polymorphisms on drug metabolism and disposition 
Most DMEs exhibit clinically relevant genetic polymorphisms. Adverse drug reactions are common; 
they are responsible for a number of debilitating side effects and are a significant cause of death 
following drug therapy (Lazarou et al., 1998). It is now clear that a significant proportion of these 
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adverse drug reactions, as well as therapeutic failures, are caused by genetic polymorphisms, 
genetically based interindividual differences in drug absorption, disposition, metabolism, or excretion. 
Most of the commercially available drugs are metabolized by the phase I cytochrome P450 
superfamily of DMEs. The clinical relevance is best-characterized for the genetic polymorphisms in 
CYP2D6, CYP2C19 and CYP2C9 (Stormer et al., 2000; Xie et al., 2004). CYP2D6 play important 
roles in the metabolism of beta-blockers, tricyclic antidepressants, antiarrythmic agents, antipsychotic 
agents and opioids. CYP2C19 is involved in the metabolism of proton-pump inhibitors whereas 
CYP2C9 metabolizes antidiabetics and anticoagulants. 
 
1.3  CYP3A in drug metabolism 
 
1.3.1  Expression and Variability 
CYP3A is considered to be the most important drug-metabolizing enzyme subfamily in the human 
body as it is responsible for the metabolism of 45-60% of currently used drugs (Fig. 2), as well as  
many steroids, environmental chemicals, and carcinogens (Shimada et al., 1994; Li et al., 1995; 
Thummel et al., 1996; Rebbeck et al., 1998; Evans and Relling, 1999; Guengerich, 1999).  
CYP3A4/5/7
CYP2E1
CYP2D6
CYP2C19
CYP2C9
CYP2C8
CYP2B6
CYP1B1
CYP2A6
CYP1A1/2
others
Epoxide 
Hydrolase
Esterases
NQO1
DPD
ADH ALDH
 
Fig.2 Relative contribution of specific enzymes to Phase I drug metabolism. 
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The percentage of Phase I metabolism of drugs contributed by each enzyme is estimated by the 
relative size of each section of the chart. ADH, alcohol dehydrogenase; ALDH, aldehyde 
dehydrogenase; CYP, cytochrome P450; DPD, dihydropyrimidine dehydrogenase; NQO1, NADPH: 
quinone oxidoreductase (adapted from (Evans and Relling, 1999)). 
 
The members of this enzyme subfamily are the most abundantly expressed CYP enzymes in the liver 
(30% or more of total CYP content) (Shimada et al., 1994), small intestinal tissue (Kolars et al., 1992; 
Kolars et al., 1994; Lown et al., 1994; Paine et al., 1997; Koch et al., 2002; Lin et al., 2002), and 
kidney (Schuetz et al., 1992; Haehner et al., 1996; Koch et al., 2002; Givens et al., 2003). The wide 
substrate spectrum of CYP3A is the reason behind their frequent involvement in drug-drug 
interactions. Drug interactions may reduce CYP3A metabolic activity through inhibition or may 
increase it through induction. Such interactions can expand the range of variability of the area under 
curve (AUC) for CYP3A substrates to about 400-fold (Thummel and Wilkinson, 1998; Levy et al., 
2001). However, the marked interindividual differences in CYP3A activity have also been reported to 
reflect genetic components (Ozdemir et al., 2000). Therefore, there has been a considerable effort to 
identify CYP3A gene mutations which might affect the expression and function of the CYP3A 
enzymes. 
The human CYP3A locus is comprised of four functional genes (CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43), but the differentiation between their products has proven difficult, due to the similarities 
in their protein sequence, in antigenic properties and due to overlapping substrate specificities (Gellner 
et al., 2001). In consequence, even though the variability in the expression is established for the three 
most important CYP3A genes (CYP3A4, CYP3A5 and CYP3A7), their respective contributions to the 
hepatic CYP3A pool and their effects on drug metabolism are still a matter of debate.  
 
Table 3. Contribution of each CYP3A enzymes to the total hepatic CYP3A protein pool 
CYP3A 
enzymes 
Contribution to the total hepatic 
CYP3A protein pool (%) 
References 
CYP3A4 40-98% 
CYP3A5 2-60% 
(Wrighton et al., 1990; Tateishi et al., 1999; 
Kuehl et al., 2001; Koch et al., 2002; Lin et al., 
2002; Westlind-Johnsson et al., 2003) 
CYP3A7 13%, 24% (Stevens et al., 2003; Sim et al., 2005) 
CYP3A43 Not detected (Domanski et al., 2001; Gellner et al., 2001; 
Westlind et al., 2001) 
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1.3.2 CYP3A polymorphisms 
The four CYP3A genes encoding their respective enzymes are localized in a 231-kb cluster on 
chromosome band 7q21-q22.1 (Brooks et al., 1988; Spurr et al., 1989; Inoue et al., 1992), and reside 
in tandem, adjacent to each other in the order: CYP3A43-CYP3A4-CYP3A7-CYP3A5 (Nelson et al., 
1996; Domanski et al., 2001; Gellner et al., 2001; Finta and Zaphiropoulos, 2002); in which the 
CYP3A43 gene is in a head-to-head orientation with its neighboring gene CYP3A4, and the other 
three genes lie in head-to-tail orientation. Two pseudogenes (Nelson et al., 2004), CYP3AP1 and 
CYP3AP2 are present between the intergenic regions of CYP3A7-CYP3A5 and CYP3A4-CYP3A7, 
respectively (Finta and Zaphiropoulos, 2000). 
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Table 4*. Ethnic distribution of variant alleles of CYP3A 
CYP3A genetic 
variants 
References Allele frequencies (%) in different ethnic groups 
  African Hispanic Caucasian Chinese Japanese 
CYP3A4
CYP3A4*1B (Rebbeck et al., 1998; Walker et al., 1998; Paris et al., 1999; Sata et al., 2000; 
Kuehl et al., 2001) 
35-67% 9.3-11% 2-9.6% 0% 0% 
CYP3A4*2 (Sata et al., 2000) 0% N.A. 2.7% 0% N.A. 
CYP3A4*3 (Sata et al., 2000) N.A. N.A. 0.47-4% 1.5% N.A. 
CYP3A4*4 (Hsieh et al., 2001) N.A. N.A. N.A. 1.5% N.A. 
CYP3A4*5 (Hsieh et al., 2001) N.A. N.A. N.A. 0.98% N.A. 
CYP3A4*6 (Hsieh et al., 2001) N.A. N.A. N.A. 0.5% N.A. 
CYP3A4*7 (Eiselt et al., 2001) N.A. N.A. 1.41% N.A. N.A. 
CYP3A4*8 (Eiselt et al., 2001) N.A. N.A. 0.33% N.A. N.A. 
CYP3A4*9 (Eiselt et al., 2001) N.A. N.A. 0.24% N.A. N.A. 
CYP3A4*10 (Lamba et al., 2002) 2% 5% 0.24-2% N.A. N.A. 
CYP3A4*11 (Eiselt et al., 2001) N.A. N.A. 0.34% N.A. N.A. 
CYP3A4*12 (Eiselt et al., 2001) N.A. N.A. 0.34% N.A. N.A. 
CYP3A4*13 (Eiselt et al., 2001) N.A. N.A. 0.34% N.A. N.A. 
CYP3A4*14 N.A. N.A. N.A. N.A. N.A. N.A. 
CYP3A4*15A (Dai et al., 2001; Lamba et al., 2002) 2-4.2% - 0% 0% 0% 
CYP3A4*16 (Lamba et al., 2002) N.A. 5% N.A. N.A. 5% 
CYP3A4*17 (Dai et al., 2001) 0% 0% 2.1% 0% 0% 
CYP3A4*18 (Dai et al., 2001) N.A. N.A. N.A. 10% N.A. 
CYP3A5
CYP3A5*2 (Jounaidi et al., 1996; Hustert et al., 2001) 0% N.A. 1.9-5% N.A. N.A. 
CYP3A5*3 (Hustert et al., 2001; Kuehl et al., 2001) 27-50% 75% 70% 65-73% 71-85% 
CYP3A5*5 (Chou et al., 2001)    0.9%  
CYP3A5*6 (Hustert et al., 2001; Kuehl et al., 2001) 13% 0% 0% 0% 0% 
CYP3A5*7 (Hustert et al., 2001) 10% 0% 0% 0% 0% 
CYP3A5*8 N.A. N.A. N.A. N.A. N.A. N.A. 
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CYP3A5*9 N.A. N.A. N.A. N.A. N.A. N.A. 
CYP3A5*10 N.A. N.A. N.A. N.A. N.A. N.A. 
CYP3A7
CYP3A7*1B (Kuehl et al., 2001) 0% N.A. 1% N.A. N.A. 
CYP3A7*1C (Kuehl et al., 2001; Burk et al., 2002) 6%  3%   
CYP3A7*1D (Kuehl et al., 2001) 0% N.A. 1% N.A. N.A. 
CYP3A7*1E (Kuehl et al., 2001) 8% N.A. 0% N.A. N.A. 
CYP3A43
CYP3A43*3 N.A. N.A. N.A. N.A. N.A. N.A. 
* N.A., not available 
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1.3.2.1 CYP3A4 genetic variability 
Identification of single nucleotide polymorphisms (SNPs) in the CYP3A genes has been an active area 
of research. Currently, 39 CYP3A4 alleles, comprising 65 SNPs have been reported (Human 
Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP3A4 allele nomenclature. Available 
from URL: http://www.imm.ki.se/CYPalleles/cyp3a4.htm.). By far the most common CYP3A4 
genetic variant is the A-392G transition (CYP3A4*1B) located in the 5’-regulatory region (Rebbeck et 
al., 1998; Westlind et al., 1999). CYP3A4*1B allelic frequency varies among different ethnic groups: 
0% in Asian, 5% in Caucasians and 54% in Africans (Chowbay et al., 2005). The other allelic variants 
occur at much lower frequencies (<1%-2%) or they are selectively prevalent in specific populations 
(Hamzeiy et al., 2002; Lamba et al., 2002; Floyd et al., 2003).  
Many studies have been carried out on functions of CYP3A4 variants. CYP3A4*1B has been studied 
to ascertain the effect of the mutation on transcriptional activity and in vivo catalytic activity 
(Amirimani et al., 1999; Ando et al., 1999). The results of studies with larger numbers of 
predominantly Caucasian liver samples demonstrate no clear association between CYP3A4*1B variant 
and CYP3A4 specific content or catalytic activity (Westlind et al., 1999; Lamba et al., 2002). 
Compared with wild-type enzyme, there was no significant difference in the rates of CYP3A4*3, 
CYP3A4*7, CYP3A4*9, CYP3A4*11 and CYP3A4*19 metabolizing the probe substrates 
testosterone, progesterone, or 7-benzyloxy-4-(trifluoromethyl) coumarin (Sata et al., 2000; Dai et al., 
2001; Eiselt et al., 2001). It means that these variants have no pronounced effect on drug metabolism 
kinetics. The individuals with CYP3A4*8 and CYP3A4*13 genotypes may have lower CYP3A4 
protein content, since these variants appear to affect steady-state enzyme levels by altering heme 
binding and/or protein stability (Eiselt et al., 2001). For CYP3A4*2, CYP3A4*10, CYP3A4*14, 
CYP3A4*15 and CYP3A4*16, there was no significant association with midazolam hydroxylation 
activity (Lamba et al., 2002). Those with CYP3A4*17 genotype exhibited in vitro a significantly 
lower turnover of testosterone and of the insecticide chlorpyrifos than those with CYP3A4*1, while 
those with CYP3A4*18 metabolized both substrates with a higher turnover (Dai et al., 2001). Subjects 
carrying CYP3A4*4, CYP3A4*5 or CYP3A4*6 exhibited below average 6 beta-hydroxycortisol to 
cortisol ratio, implying reduced catalytic activity for the corresponding protein variants (Hsieh et al., 
12 
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2001). Indeed, most of the changes in catalytic activity observed for CYP3A4 gene variants are 
relatively modest. These catalytic findings and consideration of the low allele frequencies for the 
known structural CYP3A4 variants, implies that they are not the major cause of interindividual 
differences in CYP3A-mediated drug clearance in the general population.  
 
1.3.2.2 CYP3A5 genetic variability 
The genetic basis of the CYP3A5 polymorphism has gradually been elucidated following the 
publication in 2000 by Paulussen and colleagues that demonstrated the existence of genetic variants in 
complete concordance with the polymorphic CYP3A5 expression in the liver (Paulussen et al., 2000). 
To date 10 CYP3A5 alleles, consisting of 22 SNPs, have been identified (Human Cytochrome P450 
(CYP) Allele Nomenclature Committee. CYP3A5 allele nomenclature. Available from URL: 
http://www.imm.ki.se/CYPalleles/cyp3a5.htm.). Of the variants found, CYP3A5*3 (g.6986G) is the 
only one found in all ethnic groups tested. The frequencies vary from 27% in African-Americans to 
95% in Caucasians (Hustert et al., 2001; Kuehl et al., 2001; Fukuen et al., 2002; van Schaik et al., 
2002; Hu et al., 2005; Roy et al., 2005). Other variants such as CYP3A5*6 and CYP3A5*7 affecting 
the CYP3A5 expression are relatively frequent in African subjects (10-22%) but absent in white 
subjects (Roy et al., 2005). The remaining CYP3A5 genetic variants are rare or occur at much lower 
allelic frequencies (Lamba et al., 2002; Roy et al., 2005).  
In contrast to CY3A4, CYP3A5 expression in human exhibits a bimodal distribution, with the 
proportion of CYP3A5 “high expressers” and “low expressers” varying depending on the ethnic 
background. These interethnic differences in the prevalence of the CYP3A5 polymorphism are in part 
caused by differing allelic frequencies of the major genetic determinant of this trait, the g.6986A>G 
polymorphism (Hustert et al., 2001; Kuehl et al., 2001). This variant is located in intron 3 of the 
CYP3A5 gene. The inheritance of an adenine at this position (g.6986A, CYP3A5*1) allows for 
normal generation of CYP3A5 transcripts, whereas a guanine (g.6986G, CYP3A5*3) generates a 
cryptic splice with the resulting degradation of CYP3A5 transcripts (Kuehl et al., 2001). In Caucasians 
the concordance between the presence of g.6986A and increased CYP3A5 expression is high. Among 
183 liver samples tested, all 18 livers with increased CYP3A5 protein levels had at least one allele 
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with adenine at g.6986 (Hustert et al., 2001). In samples of African origin the situation is more 
complex with the g.6986A>G polymorphism being less predictive of CYP3A5 expression (Kuehl et 
al., 2001). This is because of additional variants specific to Africans such as adenine at the 
polymorphic position g.14690G>A (also referred as CYP3A5*6 allele). This polymorphism is 
observed in 13% of CYP3A5 gene loci of African origin and results in the skipping of CYP3A5 exon 
7 transcription (Kuehl et al., 2001). The g.27131-27132insT (also referred to as CYP3A5*7 allele), 
which terminates the open reading frame of CYP3A5 at position 348, is found in approximately 10% 
of CYP3A5 gene loci in this ethnic group. Both these variants have been found in samples 
homozygous for g.6986A (Hustert et al., 2001). The functional significance of several CYP3A5 
genetic variants has been investigated. CYP3A5*2 has been reported to be present in two out of five 
liver tissues not expressing CYP3A5 protein, implying that this variant may confer protein instability 
(Jounaidi et al., 1996; Kuehl et al., 2001) or may be in strong linkage disequilibrium with other 
currently unknown mutations responsible for impaired protein expression and stability. The 
CYP3A5*5 variant produces multiple splicing products in Caco-2 cell lines (Chou et al., 2001). 
CYP3A5*6 carriers showed lower CYP3A5 protein expression and catalytic activity in three liver 
samples from African-Americans compared with the CYP3A5*1 carriers (Kuehl et al., 2001). 
CYP3A5*7 is an  insertion variant resulting in a premature stop codon and thus protein truncation 
(Chou et al., 2001; Hustert et al., 2001; Lee et al., 2003). In vitro functional data using purified P450s 
(Lee et al., 2003) showed that for both the intrinsic clearance (Vmax/Km) of testosterone and the Vmax of 
nifedipine oxidation, the rank order was: CYP3A5*1> CYP3A5*9> CYP3A5*8> CYP3A5*10. Low 
expression of CYP3A5 mRNA and protein was found to be associated with the most frequent and 
functionally important CYP3A5*3 genotype, regardless of racial ancestry (Hustert et al., 2001; Kuehl 
et al., 2001). 
 
1.3.2.3 CYP3A7 genetic variability 
To date, 6 CYP3A7 alleles were available on the CYP3A7 allele nomenclature webpage (Human 
Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP3A7 allele nomenclature. Available 
from URL: http://www.imm.ki.se/CYPalleles/cyp3a7.htm.). The most common CYP3A7 variant 
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reported is CYP3A7*2 which carries a mutation in exon 11 and occurs at a frequency of 8%, 17%, 
28%, and 62% in white, Saudi Arabian, Chinese, and African individuals, respectively (Rodriguez-
Antona et al., 2005). CYP3A7*1C allele was reported at a frequency of 3% and 6% in Caucasians and 
African-American, respectively (Kuehl et al., 2001; Burk et al., 2002). CYP3A7*1B and CYP3A7*1D 
was found to be 1% for Caucasians and was not detected in African-Americans (Kuehl et al., 2001). In 
contrast, CYP3A7*1E was only detected in African-Americans at a frequency of 8% (Kuehl et al., 
2001). 
CYP3A7, the predominant CYP3A isoform in fetal liver (de Wildt et al., 1999; Ring et al., 1999), is 
expressed polymorphically in livers of white individuals, with approximately 11% of samples 
belonging to a high-expression subgroup (Burk et al., 2002). Two-thirds of the subjects in this group 
carry either the CYP3A7*1C allele, or less frequently, the CYP3A7*1B allele, which have been 
originally described by Kuehl and colleagues (Kuehl et al., 2001). Fetal livers homozygous for 
CYP3A7*2 had similar or higher CYP3A7 protein contents than CYP3A7*1 livers (Rodriguez-
Antona et al., 2005). Kinetic studies showed that CYP3A7*2 has significantly higher catalytic 
constant (Kcat) compared with CYP3A7.1 toward dehydroepiandrosterone (DHEA). Consistently, fetal 
livers expressing CYP3A7*2 had an increased metabolism of the CYP3A7-specific substrate DHEA 
(Rodriguez-Antona et al., 2005). By analogy to CYP3A5, CYP3A7 increases the activity and 
versatility of biotransformation pathways for drugs and other xenobiotics, as well as endogenous 
compounds; as it is also concomitantly expressed in the liver, intestine, adrenal gland, prostate and 
thymus of adults.  
 
1.3.2.4 CYP3A43 genetic variability 
CYP3A43 was the last CYP3A to be discovered (Domanski et al., 2001; Gellner et al., 2001; Westlind 
et al., 2001). Thus far, CYP3A43 has not been demonstrated to produce a protein in vivo and may in 
fact be a pseudogene, although a low level activity has been described for CYP3A43 protein expressed 
in an E. coli (Domanski et al., 2001). It was therefore surprising, when Zeigler-Johnson and colleagues 
(Loukola et al., 2004; Zeigler-Johnson et al., 2004) reported an association between prostate cancer 
risk in men with a family history of this disease and the missense variant CYP3A43*3. Even more 
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recently, homozygocity for the same variant has been associated with a 2.6-fold increase in prostate 
cancer risk in African-Americans (Stone et al., 2005). Interestingly, prostate expresses more 
CYP3A43 transcripts than most other human tissues (Gellner et al., 2001). It remains unclear if these 
associations reflect a genuine CYP3A43 effect and would be its mechanism. CYP3A43 has been 
reported to contribute exons to CYP3A4 and CYP3A5 transcripts via trans-splicing, although levels of 
the resulting chimeric molecules are probably very low (Finta and Zaphiropoulos, 2000). Since the 
CYP3A locus exhibits high linkage disequilibrium (Thompson et al., 2004; Zeigler-Johnson et al., 
2004; Schirmer et al., 2006) the associations between CYP3A43*3 and prostate cancer could 
alternatively reflect the effect of a variant in another CYP3A gene. Several other CYP3A43 gene 
variants have recently been reported in a French cohort, including two nucleotide substitutions, one 
silent mutation, one missense mutation, and a frame shift mutation (Cauffiez et al., 2004), but their 
functional or clinical effects at present are unknown.  
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1.4  Investigated known and presumed substrates of CYP3A enzymes 
 
1.4.1 Testosterone 
Testosterone, the principal androgen or male sex hormone is one of the groups of compounds known 
as anabolic steroids. Testosterone is secreted mainly by the testes but it is also synthesized in small 
quantities in the ovaries, cortices of the adrenal glands, and placenta, usually from cholesterol. 
Pharmacologically, testosterone is used in the treatment of hypogonadism, cryptorchism, carcinomas, 
and menorrhagia (Darby and Anawalt, 2005). In recent years, testosterone has been increasingly used 
as an anti-aging medication (Shomali, 1997). 
The effects of testosterone (Fig. 3) in humans occur by way of two main mechanisms: by activation of 
the androgen receptor (directly or as 5α-dihydrotestosterone), and by conversion to estradiol and 
activation of certain estrogen receptors.  
 
Fig. 3 Pathways for testicular androgen and estrogen biosynthesis 
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Free testosterone is transported into the cytoplasm of target tissue cells, where it can bind to the 
androgen receptor, or it can be reduced to DHT by the cytoplasmic enzyme 5α-reductase. DHT binds 
to the same androgen receptor even more strongly than testosterone, so that its androgenic potency is 
about 2.5 times that of testosterone (Grino et al., 1990).  
Testosterone effects can be classified as virilizing and anabolic effects. Virilizing effects include 
growth of the penis, formation of the scrotum, and deepening of the voice, as well as beard and torso 
hair. Many of these effects fall into the category of secondary sex characteristics. When they occur to 
an unwanted degree in women they are termed "virilization" or "masculinization". Anabolic effects of 
testosterone include growth of muscle mass and strength, increased bone density and strength, and 
stimulation of height growth and bone maturation. 
Testosterone 6ß-hydroxylation has long been recognized as a CYP3A-mediated reaction (Fig. 4). In 
HLMs numerous studies demonstrate that selective CYP3A inhibitors diminish the 6ß-hydroxylation 
of testosterone (Wrighton et al., 1990; Newton et al., 1995; Bourrie et al., 1996). 
Specific antibodies against CYP3A inhibit the formation of 6ß-hydroxytestosterone by more than 90% 
(Gelboin et al., 1995; Mei et al., 1999; Shou et al., 2000). Studies with purified human proteins 
(Yamazaki and Shimada, 1997) and with cDNA-expressed enzymes (Waxman et al., 1991; Ono et al., 
1996) provide additional evidence that all CYP3A members catalyze testosterone 6ß-hydroxylation. 
CYP2C9 and CYP2C19 also catalyze the reaction, but at 1/10 the rate of CYP3A (Yamazaki and 
Shimada, 1997). It was concluded that testosterone 6ß-hydroxylation rate primarily reflects the 
CYP3A activity, and thus can be used as a CYP3A in vitro phenotyping probe. 
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Testosterone 6ß-hydroxytestosterone 
CYP3A
 
Fig. 4 CYP3A mediated testosterone 6ß-hydroxylation 
 
1.4.2 Tacrolimus 
Tacrolimus, a potent immunosuppressive macrolide lactone isolated from the fermentation broth of 
Streptomyces tsukabaensis (Goto et al., 1987), is a relatively specific inhibitor of T lymphocyte 
proliferation, which exerts its immunosuppressive activity mainly through binding to immunophilins 
(FK-binding proteins, FKBP). On account of these immunosuppressive properties, it is widely used in 
the prophylaxis of organ rejection after allogenic solid organ transplantation. Tacrolimus is subject to 
substantial intestinal and hepatic first-pass metabolism and its bioavailability is individually variable. 
Thus, tacrolimus elimination expressed as total body clearance varies inter-individually from 0.041 to 
0.36 L/hr/kg of body weight (Christians et al., 2002). Because of this variability in conjunction with its 
narrow therapeutic index, monitoring of whole blood concentrations of tacrolimus is frequently used 
to achieve optimal efficacy while minimizing the risk of toxicity (Oellerich et al., 1998). Tacrolimus 
undergoes O-demethylation, hydroxylation and/or oxidative metabolic reactions in the liver and in the 
intestine, and it is eliminated mostly with the bile (Christians et al., 1991; Lhoest et al., 1991; Sattler et 
al., 1992; Vincent et al., 1992; Lhoest et al., 1994; Shiraga et al., 1994). Demethylation to 13-O-
demethyltacrolimus by CYP3A is quantitatively the most important metabolic route (Fig. 5) (Sattler et 
al., 1992; Vincent et al., 1992; Karanam et al., 1994; Lampen et al., 1995). 
Several clinical studies have demonstrated that carriers of CYP3A5*1 alleles (CYP3A5 “high 
expressers”) require higher doses of tacrolimus to achieve target blood concentrations than 
homozygous carriers of the CYP3A5*3 allele (CYP3A5 “low expressers”) (Macphee et al., 2002; 
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Hesselink et al., 2003; Thervet et al., 2003; Zheng et al., 2003; Haufroid et al., 2004; Macphee et al., 
2005; Thervet et al., 2005), but it is not yet clearly understood, to what extend CYP3A5 contributes to 
tacrolimus biotransformation and why there is a clinically detectable difference although the CYP3A5 
content relative to that of CYP3A4 is even in the high expressers of CYP3A5 only about ¼.  
 
CYP3A
 Tacrolimus 13-O-demethyltacrolimus 
 
Fig. 5 13-O demethylation of Tacrolimus by CYP3A 
 
1.4.3 Aflatoxin B1 (AFB1) 
AFB1 is produced by certain Aspergillus species, which contaminate human and animal food during 
growth and after harvest. The highest exposure to AFB1 has been observed in parts of Africa, China 
and Southeast Asia, which are also characterized by a high incidence of Hepatocellular carcinoma 
(HCC) (Wild and Hall, 2000). HCC is the most common type of liver cancer and the fifth most 
common cancer in the world (Wild and Hall, 2000). Main risk factors for HCC are hepatitis B and C 
viruses, exposure to aflatoxin B1 (AFB1). Positive association has been found between individuals 
with HCC and the presence of 249ser mutation (AGG⇨AGT transversion at codon 249) in the tumor 
suppressor gene TP53 (Bressac et al., 1991; Hsu et al., 1991; Lasky and Magder, 1997; Montesano et 
al., 1997; Stern et al., 2001). Biotransformation is critical for the carcinogenic effect of AFB1. The 
four main products of AFB1 bioactivation are AFM1, AFQ1, AFB1-endo-8,9-epoxide and AFB1-8,9-
exo-epoxide (Fig. 6). The last compound is the only known genotoxic derivative, which binds to DNA 
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to form the predominating 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-AFB1 (AFB1-N7-Gua) adduct 
(Wild and Turner, 2002). AFB1-N7-Gua confers the mutagenic properties of the compound. The other 
metabolites are poorer substrates for epoxidation and, consequently, are less mutagenic, carcinogenic 
and toxic than AFB1.  
CYP3A and CYP1A2 are the major enzymes involved in the metabolism of AFB1 in adult human 
liver microsomes (Forrester et al., 1990; Ramsdell et al., 1991; Ueng et al., 1995; Patterson et al., 
1999). CYP3A4 produces predominantly AFB1-8,9-exo-epoxide and AFQ1, whilst CYP1A2 leads to 
the formation of AFB1-8,9-exo and endo-epoxide, and of AFM1. However, there is still some 
discrepancy regarding the relative importance of CYP1A2 and CYP3A4 in human AFB1-8,9-exo-
epoxide formation. CYP3A7 plays a role in the bioactivation of AFB1 to 8,9-exo-epoxide (Kitada et 
al., 1989; Kamataki et al., 1995; Yamada et al., 1998). CYP3A5 also metabolizes AFB1, however 
mainly to the exo-epoxide, with much less efficient formation of the detoxification product, AFQ1 
(Wang et al., 1998). An association between increased levels of aflatoxin-albumin adducts and 
CYP3A5 “high expresser” status, particularly in individuals with low concomitant CYP3A4 
expression, has been reported in AFB1-exposed Gambians (Wojnowski et al., 2004). 
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AFQ1
AFB1
AFP1
AFM1
AFB1-exo 8,9-epoxide
Aflatoxin-GSH conjugate
AFB1-endo 8,9-epoxide
Aflatoxin-2,3-dihydrodiol
Aflatoxin-DNA
AFM1-epoxide Aflatoxin-N7-guanine
Aflatoxin-mercaptopuric  acid
Aflatoxin-Albumin
Aflatoxin-dialdehyde
Aflatoxin-dialcohol
Aflatoxin-Glucoronide
Urine
Urine
Urine
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UrineUrine
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1A2
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Fig. 6 Biochemical pathways of AFB1 metabolism in humans. 1A2, CYP1A2; 3A4, CYP3A4; 3A5, 
CYP3A5; 3A7, CYP3A7; GST, glutathione S-transferase; mEH, microsomal epoxide hydrolase; 
AFAR, aflatoxin aldehyde reductase (Adapted from Wild and Turner (Wild and Turner, 2002)). 
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2  AIMS OF THE STUDY 
The aims of this thesis were to investigate the impact of CYP3A5 genetic polymorphisms for humans 
in health and disease. In this context, four specific questions should be answered: 
 
1. To investigate the experimental determinants of CYP3A5 compared to CYP3A4 catalytic 
activity in vitro by optimizing the details of enzyme kinetic analysis using testosterone as an 
index substrate for CYP3A4 and CYP3A5 enzymes. In this context, different sources of 
artificially expressed CYP3A enzymes and cytochrome reductase and different ratios between 
CYP and reductase/cytochrome b5 should be compared. 
2. To assess the relative contribution of CYP3A5 to the overall hepatic CYP3A activity among 
Caucasian. For this purpose, we used 6ß-hydroxylation of testosterone as a CYP3A specific 
probe, baculovirus-expressed CYP3A4 and CYP3A5 enzymes, microsomes isolated from 47 
Caucasian livers with quantified amounts of CYP3A4 and CYP3A5 proteins, genotype-
phenotype correlation analysis, as well as assessment of relative contributions based on the 
hepatic abundance approach.  
3. To investigate the contribution of CYP3A5 to the in vitro hepatic metabolism of the macrolide 
immunosuppressive drug tacrolimus using baculovirus-expressed enzymes, microsomes 
derived from low and high CYP3A5 expressers, genotype-phenotype analysis, assessment of 
relative contribution based on the hepatic abundance approach and the prediction of 
tacrolimus pharmacokinetic clearance. 
4. To evaluate the contribution of CYP3A5, as well as that of CYP3A4, CYP3A7 and CYP1A2 
to the hepatic production of the reactive and carcinogenic aflatoxin B1 (AFB1) metabolite 
AFB1-8,9-epoxide using baculovirus-expressed enzymes, microsomes derived from low and 
high CYP3A5 expressers, genotype-phenotype analysis and assessment of relative 
contribution based on the hepatic abundance approach. 
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3  MATERIALS AND METHODS  
To assess the impact of CYP3A5 genetic polymorphism on the biotransformation of drugs and 
environmental toxins, microsomes, RNA and DNA were isolated from human liver tissues. The 
genotyping of human liver samples was assessed by allelic discrimination. The amount of CYP 
proteins and transcripts were determined using western blot analysis and Real Time PCR (TaqMan 
assay) analysis, respectively. The microsomes were then incubated with the investigated known and 
presumed CYP3A substrates. The produce metabolites were identified and quantified using HPLC and 
LC-MS/MS analysis. Enzyme kinetic data analysis was finally used to determine enzyme kinetic 
parameters. More specific details about the materials and assays used during this investigation are 
described within this section. 
 
3.1  Materials 
 
3.1.1 Instruments 
Instruments Manufacturer 
HPLC pump L-7100 Merck, Darmstadt, Germany 
HPLC autosampler L-7200 Merck, Darmstadt, Germany 
HPLC ultraviolet detector L-7400 Merck, Darmstadt, Germany 
LC-MS/MS API 2000 Applied Biosystems, Foster city, USA 
Biophotometer (Instrument designed for analysis 
of DNA, RNA, Oligonucleotides and  Proteins) 
Eppendorf, Hamburg, Germany 
Kendro Laboratory Products, Germany 
Beckman, Munich, Germany  
Centrifuges 
Eppendorf, Hamburg, Germany 
Sequence detection system ABI PRISM 7900HT 
(Real-Time Quantitative PCR System) 
Applied Biosystems, Foster city, USA 
Biorobot (Instrument designed for automating 
DNA isolation using a solid phase extraction 
method) 
Qiagen, Hilden, Germany 
Tecan Ultra (Microtiter plate - Fluorimeter) Tecan, Crailshaim, Germany 
pH Meter Knick, Berlin, Germany 
Water bath (for microsomal incubation) Kötterman, Uetze, Germany 
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3.1.2 Consumable materials 
Products Manufacturer 
Adhesive PCR film ABgene, Hamburg, Germany 
Adhesive PCR foil seals ABgene, Hamburg, Germany 
Cuvette Eppendorf, Hamburg, Germany 
Tubes 15 ml Greiner, Flacht, Germany 
Tubes 50 ml Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Tubes 1.5 ml with cap Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
HPLC caps GL45 Merck, Darmstadt, Germany 
Reaction tubes Eppendorf, Hamburg, Germany 
Flat Cap Strips ABgene, Hamburg, Germany 
Nitrile examination gloves Ansell, München, Germany 
Latex gloves Kimberley-Clark, Koblenz, Germany 
Cytostatic Gloves  Berner International, Elmshorn, Germany 
Deuterium bulb for HPLC photometric 
detector 
Merck, Darmstadt, Germany 
Lichrospher 100 CN column (particle 
size, 5 µm; 125 X 4.6 mm) 
Merck, Darmstadt, Germany 
Nucleosil C18 column (particle size, 5 
µm; 250 x 2.1 mm) 
MZ-Analysentechnik, Mainz, Germany 
Econosphere C18 column (particle size, 
5µm; 4.6 x 250 mm) 
Alltech, Unterhaching, Germany 
Extraction C18 catridge (4.0 x 3.0 mm) Phenomenex, Aschaffenburg, Germany 
Optical adhesive covers Applied Biosystems, Foster city, USA 
Pipettes Eppendorf, Hamburg, Germany 
Pipettes with filter Sarstedt, Nürmbrecht-Rommelsdorf, Germany 
Microtiter optical sterile plate 96-well Applied Biosystems, Foster city, USA 
Protective clothing  Berner International, Elmshorn, Germany 
Polyvinylidene fluoride membranes Roche Diagnostics, Mannheim, Germany 
Tank Blot Cell for Western blot Biorad, Hercules, CA, USA 
 
3.1.3 Chemicals 
Chemicals Manufacturer 
Ampli TaqTM DNA polymerase Applied Biosystems, Foster city, USA 
Ammonium acetate pro analysi Merck, Darmstadt, Germany 
Dexoynucleotide triphosphates (dNTP set) ABgene, Hamburg, Germany 
Taq DNA polymerase Qiagen, Hilden, Germany 
Random Primer pd (N) 6 Roche, Mannheim, Germany 
TaqMan universal PCR master mix Applied Biosystems, Foster city, USA 
Tris base AppliChem, Darmstadt, Germany 
Glycine zur Analyse AppliChem, Darmstadt, Germany 
Sodium Dodecyl Sulfate  AppliChem, Darmstadt, Germany 
N, N, N’, N’- Tetramethylethylenediamine AppliChem, Darmstadt, Germany 
Ammonium persulfat zur Analyse  AppliChem, Darmstadt, Germany 
EDTA Merck, Darmstadt, Germany 
Glycerine Roth, Karlsruhe, Germany 
Bromphenol blue Roth, Karlsruhe, Germany 
Ponceau S AppliChem, Darmstadt, Germany 
Pefabloc SC (protease inhibitor, prevents 
non-specific covalent modification of 
proteins) 
Roche, Mannheim, Germany 
Sucrose Merck, Darmstadt, Germany 
DTT Sigma, Deisenhofen, Germany 
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ß-Mercaptoethanol AppliChem, Darmstadt, Germany 
NaCl AppliChem, Darmstadt, Germany 
Tween-20 AppliChem, Darmstadt, Germany 
DL-Norleucin AppliChem, Darmstadt, Germany 
DNA standard 1 kb Rapidozym, Berlin, Germany 
Testosterone Steraloids, Wilton, USA 
6ß-hydroxytestosterone Sigma, Deisenhofen, Germany 
NADPH Roche, Mannheim, Germany 
Protein standard (BSA) Biorad, Hercules (CA, USA) 
Tacrolimus Fujisawa, Osaka, Japan 
13,15-O-didemethyltacrolimus Dade Behring, Liederbach, Germany 
13,31-O-didemethyltacrolimus Dade Behring, Liederbach, Germany 
13-O-demethyltacrolimus Prof. Uwe Christians, University of Colorado Health 
Sciences Center, Denver, USA 
15-O-demethyltacrolimus Prof. Uwe Christians, University of Colorado Health 
Sciences Center, Denver, USA 
31-O-demethyltacrolimus Prof. Uwe Christians, University of Colorado Health 
Sciences Center, Denver, USA 
Aflatoxin B1 Sigma, Deisenhofen, Germany 
Aflatoxin Q1 Sigma, Deisenhofen, Germany 
Aflatoxin M1 Sigma, Deisenhofen, Germany 
Aflatoxin G1 Sigma, Deisenhofen, Germany 
AFB1-GSH-conjugate PD. Dr. A. Seidel, Biochemical Institute of 
Environmental Carcinogens, Grosshansdorf, Germany 
Reduced glutathione (GSH) Sigma, Deisenhofen, Germany 
di-sodium hydrogen phosphate Merck, Darmstadt, Germany 
SuperSignal WestDura 
Chemiluminescence Substrate  
Pierce, St Augustin, Germany 
 
3.1.4 Kits/Reagents 
Reagents Manufacturer 
Bradford reagent Biorad, München, Germany 
PicoGreen ds DNA reagent Mobitec, Goettingen, Germany 
Protein Assay Dye Reagent Biorad, Hercules, CA, USA  
Super signal west pico kit Pierce biotechnology, Rockford, USA 
Qiagen Blood Kit Qiagen, Hilden, Germany 
Tissue DNA kit Qiagen, Hilden, Germany 
RNeasy kit for RNA isolation Qiagen, Hilden, Germany 
 
3.1.5 Solvents 
Solvents Manufacturer 
Acetone pro analysi Geyer, Nürnberg, Germany 
Acetonitrile pro analysi Geyer, Nürnberg, Germany 
Methanol pro analysi Geyer, Nürnberg, Germany 
Ethanol pro analysi Geyer, Nürnberg, Germany 
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3.1.6 Enzymes 
Enzymes Manufacturer 
SP6, T7 RNA polymerase Promega, Mannheim, Germany 
RQ-DNase Promega, Mannheim, Germany 
 
3.1.7 Drug metabolizing enzymes 
Materials Type Manufacturer 
Liver samples Collection during surgical 
interventions 
Department of Surgery, University 
Medical Center Charité, Humboldt 
University, Berlin, Germany 
HGO3 Natutec, Frankfurt am Main, 
Germany 
HG64 Natutec, Frankfurt am Main, 
Germany 
HG74 Natutec, Frankfurt am Main, 
Germany 
HH31 Natutec, Frankfurt am Main, 
Germany 
HH54 Natutec, Frankfurt am Main, 
Germany 
HH47 Natutec, Frankfurt am Main, 
Germany 
HH91 Natutec, Frankfurt am Main, 
Germany 
HG95 Natutec, Frankfurt am Main, 
Germany 
HH108 Natutec, Frankfurt am Main, 
Germany 
HH86 Natutec, Frankfurt am Main, 
Germany 
HH3 Natutec, Frankfurt am Main, 
Germany 
HH1 Natutec, Frankfurt am Main, 
Germany 
HH89 Natutec, Frankfurt am Main, 
Germany 
HH48 Natutec, Frankfurt am Main, 
Germany 
Single donor human liver 
microsomes 
HH9 Natutec, Frankfurt am Main, 
Germany 
Pooled human liver microsomes HLM Natutec, Frankfurt am Main, 
Germany 
CYP1A1/OR Natutec, Frankfurt am Main, 
Germany 
CYP1A2/OR Natutec, Frankfurt am Main, 
Germany 
CYP2A6/OR Natutec, Frankfurt am Main, 
Germany 
CYP2A6/OR/b5 Natutec, Frankfurt am Main, 
Germany 
Baculovirus-derived microsomes 
CYP1B1/OR Natutec, Frankfurt am Main, 
Germany 
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CYP2B6/OR Natutec, Frankfurt am Main, 
Germany 
CYP2B6/OR/b5 Natutec, Frankfurt am Main, 
Germany 
CYP2C8/OR/b5 Natutec, Frankfurt am Main, 
Germany 
CYP2C9*1/OR Natutec, Frankfurt am Main, 
Germany 
CYP2C9*1/OR/b5 Natutec, Frankfurt am Main, 
Germany 
CYP2C9*3/OR Natutec, Frankfurt am Main, 
Germany 
CYP2C19/OR/b5 Natutec, Frankfurt am Main, 
Germany 
CYP3A4/OR/b5 Natutec, Frankfurt am Main, 
Germany 
CYP3A4/OR Natutec, Frankfurt am Main, 
Germany 
CYP3A5/OR Natutec, Frankfurt am Main, 
Germany 
CYP3A7/OR/b5 Natutec, Frankfurt am Main, 
Germany 
OR/b5 Natutec, Frankfurt am Main, 
Germany 
Cytochrome b5 Purified Panvera, Karlsruhe, Germany 
NADPH-Oxidoreductase Purified Panvera, Karlsruhe, Germany 
Rat glutathione S-transferase 
(GST) 
Purified Sigma, Deisenhofen, Germany 
 
3.1.7 Oligonucleotides* 
Oligonucleotide Sequence 
CYP1A1 PCR primers Forward 5’-CAA GGA CCT GAA TGA GAA GTT CTA CAG-3’ 
Reverse 5’-TGG GGT TCT CAT CCA GCT G-3’ 
CYP1A1 probe FAM-TGA GAA GGG CAA CAT CCG GGA CAT-TAMRA 
CYP3A4 PCR primers Forward 5’-TCA GCC TGG TGC TCC TCT ATC TAT-3’ 
Reverse 5’-AAG CCC TTA TGG TAG GAC AAA ATA TTT-3’ 
CYP3A4 probe (absolute 
quantification) 
TCC AGG GCC CAC ACC TCT GCC T 
CYP3A5 PCR primers Forward 5’-TTG TTG GGA AAT GTT TTG TCC TAT C-3’ 
Reverse 5’-ACA GGG AGT TGA CCT TCA TAC GTT-3’ 
CYP3A5 probe (absolute 
quantification) 
TAT TTA TGA CTG TCA ACA GCC TAT GCT GGC TAT CA 
* All oligonucleotides were purchased from Applied Biosystems, Foster City, USA 
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3.1.8 Antibodies 
Antibodies Type Manufacturer 
Anti-human CYP3A4/5, Cat. 
No. 458334 
Monoclonal antibody, 
Immunoinhibition 
Natutec, Frankfurt am Main, 
Germany 
Anti-human CYP1A2, Cat. 
No. P2733 
Monoclonal antibody, Western 
Blot 
Panvera, Karlsruhe, Germany 
Rabbit Anti-human CYP3A4, 
Cat. No. 458234 
Polyclonal antibody, Western 
Blot 
Natutec, Frankfurt am Main, 
Germany 
Rabbit Anti-human CYP3A5, 
Cat. No. 458235 
Polyclonal antibody, Western 
Blot 
Natutec, Frankfurt am Main, 
Germany 
 
3.2  Methods 
 
3.2.1 Genotyping 
3.2.1.1 Isolation of genomic DNA 
Genomic DNA was isolated from blood or liver samples using Biorobot or Qiagen blood and tissue 
DNA isolation kits.  
 
3.2.1.2 RNA Isolation and cDNA synthesis 
Following homogenization, total RNA was isolated using RNeasy kit. cDNA from liver samples was 
synthesized from 1 µg of total RNA using random hexamer primers (0.1 A260 units), dNTPs (0.3 mM), 
and 50U of SuperScript reverse transcriptase in a total volume of 30 µl using the buffer and reaction 
conditions provided by Invitrogen. cDNA samples were diluted to a final concentration of 10 ng/µl of 
the total RNA taken for reverse transcription, aliquoted, and stored at – 80°C. 
 
3.2.1.3 DNA and RNA quantification 
DNA and RNA concentrations were determined photometrically at 260 nm using the Biophotometer 
6313 according to the manufacturer’s guideline. 
 
3.2.1.4 Allelic discrimination (determination of CYP3A5*3 SNP) 
CYP3A5 gene was amplified by real time polymerase chain reaction (RT-PCR) using primers 5’-
TTGTTGGGAAATGTTTTGTCCTATC-3’ (forward) and 5’-ACAGGGAGTTGACCTTCATACGT 
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T-3’ (reverse). The presence of the SNP and of the wild-type sequence CYP3A5*1 was 
simultaneously detected by use of 2 TaqMan MGB probes (Applied Biosystems, Foster city, CA) with 
sequence TGTCTTTCAATATCTCTTC labelled with FAM fluorescence reporter dye and probe 
TGTCTTTCAGTATCTCTT labelled with VIC fluorescence reporter dye. Allelic discrimination was 
accomplished by real-time PCR amplification performed with the ABI PRISM 7900 sequence 
detection system (Applied Biosystems) with the following conditions: 50°C for 2 min, then 95°C for 
10 min, followed by 35 cycles of amplification at 92°C for 15 s and 62°C for 1 min. Data were 
analyzed with the sequence detector software (version 2.1; Applied Biosystems). 
 
3.2.2 TaqMan analysis (RT-PCR) 
Plasmids containing CYP3A4 and CYP3A5 cDNAs were obtained by PCR amplification and 
subcloning of reverse-transcribed liver mRNA using gene-specific primer pairs. Following 
linearization, sense mRNAs were obtained by in vitro transcription using SP6 or T7 RNA polymerase. 
Plasmid DNA was removed through digestion with RQ-DNase, and transcribed RNA was purified by 
phenol/chloroform extraction and precipitation. RNA yield was determined photometrically, and the 
number of transcripts per microgram of in vitro RNA was calculated based on the length of the 
respective RNA. cDNAs species were then synthesized as described above and serial 10-fold dilutions 
from 106 to 100 copies were used as calibration curves. 
mRNA Expression levels were quantified by real-time quantitative PCR using the Applied Biosystems 
PrismTM Sequence Detection System 7700 (SDS7700). Oligonucleotides and TaqMan probes were 
developed using Primer Express software (Applied Biosystems). TaqMan probes were labelled on 5’ 
end with the reporter dye 6-carboxy-fluorescein and on 3’ end with the quencher 6-carboxy-
tetramethylrhodamin. Usually, cDNA derived from 10 ng of total RNA was used for one TaqMan 
reaction. In case of low copy numbers, the amount was increased to 40 ng. TaqMan PCR 
amplifications were performed using the Universal Mastermix from Applied Biosystems or the 
TaqMan reaction system from Eurogentec. The conditions consisted of 40 cycles of 15 s at 95°C and 1 
min at 60°C, following an initial step of 10 min at 95°C. Transcript numbers were then calculated 
using linear regression analysis from their respective calibration curves. The expression level of 18S 
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rRNA was determined using commercially available, predeveloped TaqMan assays (Applied 
Biosystems). Normalized expression data were obtained by dividing CYP3A transcript numbers by 
those of 18S rRNA. All assays were performed in triplicates. Analyses of most samples were 
performed at least twice with independent reverse transcription and TaqMan analysis. 
 
3.2.3 In vitro metabolism 
 
3.2.3.1 Human liver samples 
Liver samples used in the testosterone study were collected during surgical interventions conducted at 
the Department of Surgery, University Medical Center Charité, and Humboldt University in Berlin, 
Germany. The donors were white Europeans. The liver samples included nontumorous tissue 
surrounding primary liver tumors and metastases of various tumors or liver material surgically 
removed for other reasons. Medical histories were evaluated in respect of treatment with known 
CYP3A inducers. The study was approved by the local ethics committee and conducted in accordance 
with the declaration of Helsinki.  
The liver samples and derived microsomes used in tacrolimus and aflatoxin B1 studies were obtained 
from Natutec and are described in more detail in Materials, section 3.1.7 (Drug metabolism enzymes). 
 
3.2.3.2 Preparation of Human liver microsomes 
The preparation of human liver microsomes (HLM) was carried out by subcellular fractionation as 
described elsewhere (Pearce et al., 1996). In summary, liver tissue in homogenization buffer (20 mM 
Tris pH 7.4 at 4°C, 5 mM sodium EDTA, 254 mM sucrose, 0.2 mM Pefabloc SC) was weighted in a 
tumbler, minced with scissors, homogenized subsequently with an Ultraturrax homogenizer at 9,500 
rpm for 30 seconds twice and with a Potter-Elvehjem (Glass tube) tissue grinder at 1000 rpm for 30 
min. The obtained homogenate was centrifuged by 3000 g for 30 minutes in an Eppendorf 5810R 
centrifuge. The supernatant was removed and centrifuged by 17000 g for 30 minutes at +2°C in a J2-
21M/E Beckman centrifuge. Then the obtained supernatant was removed and centrifuged by 100000 g 
for 60 minutes at +4°C in a L8-70 M Beckman Ultracentrifuge. The resulting supernatant (the 
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cytosolic fraction) was removed and stored at -80°C for other research purposes. The resting pellet 
(human liver microsomes) was resuspended in microsomal buffer (20 mM Tris pH 7.4 at 4°C, 5 mM 
sodium EDTA and 254 mM sucrose) and homogenized with Potter-Elvehjem tissue grinder at 1000 
rpm. The microsomes were then aliquoted and stored at -80°C. 
 
3.2.3.3 Protein quantification 
The protein quantification in microsomal preparations was assessed using the Bradford method 
(Bradford, 1976) which is based on the observation that the absorbance maximum for an acidic 
solution of Coomassie Brilliant Blue G-250 shifts from 465 nm to 595 nm when binding to protein 
occurs. Both hydrophobic and ionic interactions stabilize the anionic form of the dye, causing a visible 
color change. In summary, the test samples for blank, BSA standards and the protein samples to be 
tested (unknown samples) were generated.. The concentration of protein standards (BSA) ranged from 
2 to 20 µg /µl. The dye reagent (1:5 diluted in deionised water) was added to the samples which were 
then allowed to incubate for 15 min. Thereafter, each sample was measured at 595 nm using a UV-
visible spectrophotometer (Biophotometer). The absorbance of BSA standard was plotted as a linear 
function of its theoretical concentration (“y = mx + b”, where y = absorbance at 595 nm and x = 
protein concentration). Using this equation, the protein concentration of each unknown protein 
samples was calculated based on their measured absorbance. 
 
3.2.3.4 Western Blot analysis 
 
3.2.3.4.1 CYP3A4/5 
Protein expression of CYP3A4 and CYP3A5 in liver samples was determined by Western blot using 
CYP3A4- and CYP3A5-specific antibodies. To obtain total protein homogenate, powdered liver tissue 
was homogenized in 0.1 M Tris-Cl pH 7.4, 1 mM EDTA, 1 mM Pefabloc, 1 µg/ml leupeptin with a 
Potter Elvehjem homogenizer (glass/Teflon) for 2 min at 1000 rpm. Homogenates were then sonicated 
for 30 s at 12 W and stored at – 80°C. For western blotting 12.5 µg microsomal protein homogenate or 
40 µg total protein homogenate were separated in a 10% SDS-polyacrylamide gel and transferred to 
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polyvinylidene fluoride membranes in a TankBlot Cell by electroblotting at 70 mA for 1.5 hour in 25 
mM Tris/40 mM DL-norleucin/20% methanol transfer buffer. Following the transfer, the membranes 
were blocked for 60 min in 5% (w/v) skim milk, TBS, 0.1% (v/v) Tween-20 (blocking buffer). 
Incubation with isoform-specific primary antibodies was performed for 1 hour as follows: rabbit anti-
CYP3A4 1:500 in blocking buffer, rabbit anti-CYP3A5 1:1000 in 1% (w/v) skim milk, TBS, 0.1% 
Tween-20. Secondary antibody (anti-rabbit IgG-peroxidase Fab-fragments, 1:20 000, Dianova) 
incubations were carried out in blocking buffer for 30 min. 3A4 and 3A5 bands were detected with 
SuperSignal WestDura chemiluminescence substrate (Pierce, St Augustin, Germany) and a digital 
CCD-luminescence camera (LAS-1000 luminescent image analyzer, Fuji). Signal quantification was 
performed with AIDA software (Raytest, Straubenhardt, Germany). Protein expression levels were 
calculated based on calibration curves obtained with microsomal protein from human lymphoblasts 
expressing recombinant CYP3A4, or of microsomal protein from baculovirus infected insect cells 
expressing recombinant CYP3A5. The calibration curves contained 50, 125, 250, 500, 1000 fmol of 
CYP3A4 or 12.5, 25, 50, 100, 200 fmol CYP3A5. The apoprotein content of CYP3A4 and CYP3A5 in 
these calibration curves was investigated by western blot using heterelogously expressed, purified 
CYP3A4 and CYP3A5 (see above) and two different polyclonal antibodies which recognize both 
CYP3A4 and CYP3A5. 
 
3.2.3.4.2 CYP1A2 
The quantification of CYP1A2 protein in human liver microsomes was carried out by immunoblotting 
analysis using antibody against human CYP1A2 (anti-P450 1A2 monoclonal antibody). Microsomal 
protein (0.005 to 0.05 pmol varying amounts of recombinant CYP1A2 standard and 5 µg of liver 
microsomal protein) was denatured for 3 min at 100°C in 125 mM Tris buffer (pH 6.8) containing 2 
mM EDTA, 4% SDS, 20% glycerol, 2% ß-mercaptoethanol and 0.02% bromphenol blue. 
Recombinant CYP1A2 (BD Gentest) was used to generate calibration standard in concentrations 
ranging from 0.005 to 0.05 pmol/lane. Protein was separated on a 7.5% SDS-polyacrylamide gel and 
transferred to polyvinylidene fluoride membranes (Roche Diagnostics, Mannheim, Germany) by 
electroblotting at 70 mA for 1 hour in 25 mM Tris/40 mM DL-norleucin/20% methanol transfer 
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buffer. The blots were blocked for 1 hour with 3% BSA in TBS-T (0.1% Tween-20, 15 mM sodium 
chloride, and 1 mM Tris; pH 7.4). The blots were then incubated for 1 hour with primary antibody 
(monoclonal antibody mouse anti-human P450 1A2 1:2500 in 1% BSA/TBS-T buffer), washed, 
incubated with anti-mouse IgG peroxidase conjugate (1:20000 in 1% BSA/TBS-T buffer) for 1 hour, 
and washed again. CYP1A2 protein was detected by means of a chemoluminescence reaction. Blots 
were exposed to film, developed, and quantified by use of Quantity One 4.2.1 software (Biorad). The 
calibration curve was linear within the range of 0.005 to 0.05 pmol. 
 
3.2.3.5 In vitro incubation 
3.2.3.5.1 Testosterone 
250 µl of testosterone solution in methanol (ranging from 20 to 160 µM) were evaporated under a 
stream of nitrogen in Eppendorf tubes. Testosterone was then dissolved in 40 µl of 50 mM potassium 
phosphate buffer (pH 7.4). Baculovirus-expressed (BE) cytochrome P450 or HLM pre-diluted in the 
same phosphate buffer were added in a volume of 50 µl. The reaction (total volume 100 µl) was 
initiated by the addition of 10 µl of 20 mM NADPH, dissolved freshly in the same phosphate buffer, 
and allowed to proceed for 5-20 min at 37°C in opened Eppendorf tubes in a shaking water bath. In 
some experiments, the incubation mixture (final volume 100 µl) was supplemented with purified 
NADPH-oxidoreductase and/or purified cytochrome b5 following a previously described method 
(Evert et al., 1997). Specifically, after addition, the mixtures were vortexed and left to stand for 15 min 
at room temperature before initiation of metabolism experiments. Thus, the incubations consisted of 
(final concentrations given) 50 mM potassium phosphate buffer (pH 7.4), BE cytochrome P450 (4-20 
pmol/100 µl) HLM (25-200 µg protein/100 µl), 2 mM NADPH and 5 µM to 400 µM testosterone in a 
final volume of 100 µl. The reactions were stopped by adding ice-cold methanol (100 µl). The 
resulting mixture was centrifuged at 13000 rpm for 5 min. 100 µl of the supernatant were used for 
HPLC analysis. The formation of 6ß-hydroxytestosterone was linear with time between 5 and 20 min 
and with the protein over the range 25 to 250 µg (HLM) and 4 to 20 pmol P450 (BE). 
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Table 4 In vitro microsomal incubation (example of experimental protocol) 
Testosterone final concentration in 100 µl incubation volume  
5 µM 25 µM 50 µM 100 µM 200 µM 400 µM 
Testosterone 50 µM in methanol 
(µl) 
10 50 100 200   
Testosterone 160 µM in methanol 
(µl) 
    125 250 
Methanol (µl) 240 200 150 50 125  
Evaporation/ N2, 37°C (min) 5 5 5 5 5 5 
Addition of phosphate buffer (µl) 40 40 40 40 40 40 
Pre-incubation (min) 5 5 5 5 5 5 
Addition of human liver microsomal 
solution (2 µg/µl) in phosphate 
buffer (µl) 
 
50 
 
50 
 
50 
 
50 
 
50 
 
50 
Pre-incubation (min) 5 5 5 5 5 5 
Addition of 20 mM NADPH (µl) 10 10 10 10 10 10 
Incubation in opened Eppendorf 
tubes (min) 
10 10 10 10 10 10 
Addition of ice cold methanol (µl) 100 100 100 100 100 100 
Centrifugation at 13000 rpm (min) 5 5 5 5 5 5 
 
3.2.3.5.2 Tacrolimus 
The in vitro microsomal incubation of tacrolimus was conducted as described in the above 
experimental protocol (Table 4). Precisely, stock solutions of tacrolimus ranging from 5 to 25µM were 
prepared in methanol. Samples were evaporated under N2, dissolved in 100 mmol/L potassium 
phosphate buffer (pH 7.4), and supplemented with either HLM or baculovirus-expressed cytochrome 
P450. The final incubation volume was 100 µL. The end concentration of tacrolimus ranged from 0.5 
to 12.5 µM. The reaction mixture with CYP3A4/OR or CYP3A5/OR was additionally supplemented 
with purified cytochrome b5 (P450: b5 ratio of 1:1) following a previously described method (Evert et 
al., 1997) prior to the start of the reaction with NADPH. Specifically, after addition, the mixtures were 
vortexed and left to stand for 15 min at room temperature before initiation of metabolism experiments. 
The reaction was initiated through addition of NADPH (final concentration 1 mM), allowed to 
proceed for 10 min, and stopped using 200 µl of a freshly prepared stop solution composed of 0.3 
mol/L ZnSO4/methanol (3:7 v/v) containing internal standard (ascomycin 25 µg/L). Following 
reaction termination, the incubation mixtures were centrifuged at 10000 g for 5 min. Supernatants 
were transferred into new tubes and 100 µl used for the LC-MS/MS analysis. The formation of 13-O-
demethyltacrolimus was linear with time between 5 and 20 min and with protein over the range from 5 
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to 50 µg for HLM and from 1 to 8 pmol for baculovirus-expressed CYP3A. The end concentrations of 
tacrolimus ranged from 0 to 12.5 µmol/L. The substrate consumption did not exceed 15% during the 
incubation time (10 min). 
 
3.2.3.5.3 Aflatoxin B1 
Stock solutions of AFB1 (ranging from 50 to 500 µM) were prepared in methanol and were allowed to 
evaporate under N2. The following components were added: 100 mmol/L potassium phosphate buffer 
(pH 7.4), 5 mmol/L reduced glutathione, purified rat liver glutathione S-transferase (0.2 mg/ml) and 
HLM or baculovirus-expressed cytochrome P450. The final incubation volume was 100 µL. The end 
concentration of AFB1 ranged from 25 to 500 µM. The reaction mixture with CYP3A4/OR or 
CYP3A5/OR was additionally supplemented with purified cytochrome b5 (P450: b5 ratio of 1:1) prior 
to the start of the reaction with NADPH, following a previously described method (Evert et al., 1997). 
Specifically, after addition, the mixtures were vortexed and left to stand for 15 min at room 
temperature before initiation of metabolism experiments The reaction was initiated through addition of 
NADPH (final concentration 1 mM), allowed to proceed for 30 min, and stopped by the addition of 
100 µl ice-cold methanol containing 10 µM AFG1 as an internal standard. The incubation mixtures 
were then centrifuged at 10000 g for 5 min. Supernatants were transferred into new tubes and 100 µl 
were used for the HPLC analysis. The formation of AFQ1 and AFBO was linear with time between 10 
and 30 min and with protein  rangingfrom 100 to 500 µg for HLMs and from 20 to 100 pmol for 
baculovirus-expressed cytochromes. The substrate consumption was <15% over the incubation time 
(30 min). 
 
3.2.3.6 Immunoinhibition 
In immunoinhibition experiments, HLM or BE enzymes in phosphate buffer were supplemented with 
a monoclonal inhibitory antibody (MAB 3-29-9) against human P450 3A4/5 (Gelboin et al., 1995) at a 
ratio of 10 pmol P450 to 100 µg antibody, and incubated for 15 min on ice. Thereafter, the incubates 
were added to testosterone (final concentration 200 µM), dissolved in potassium phosphate buffer, and 
the activity measurements carried out and terminated as described above.   
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3.2.4 HPLC analysis 
 
3.2.4.1 Testosterone 
Following reaction termination, the incubation mixtures were centrifuged at 13000 rpm for 5 min. 
Supernatants were transferred into new tubes and 100 µl used for HPLC analysis. The HPLC system 
consisted of a L-7100 pump (Merck, Germany) and a Lichrospher 100 CN column (particles of silica 
with γ-cyanopropyl function, particle size, 5 µm; 100 Å, 125 X 4.6 mm ID, Merck, Germany). The 
mobile phase consisted of 78% (v/v) of 50 mM sodium phosphate buffer (pH 6.0), 16.5% (v/v) 
methanol and 5.5% (v/v) acetonitrile. The flow rate was 0.8 ml/min at room temperature. The 
absorbance was measured at 242 nm with an ultraviolet (UV) detector (L-7400 Lachrom, Merck, 
Germany). The retention times of 6ß-hydroxytestosterone and testosterone were 5.35 and 15.05 
minutes, respectively.  
 
3.2.4.2 Aflatoxin B1 
The HPLC system consisted of a L-7100 pump (Merck, Germany) and an Alltech Econosphere C18 
column (particles of silica with octadecyl derivative, particle size, 5µm, 80 Å 4.6 x 250 mm, Alltech, 
Deerfield, IL 60015). Peaks were eluted using a gradient program with solvent A (75% 50 mM sodium 
phosphate buffer (pH 3.0) with 25% methanol) and solvent B (methanol). Flow rate was 1 ml/min. 
The solvent gradient began with 90% A, 10% B, reaching 65% A, 35% B at 15 min, and 49% A, 51% 
B at 20 min, after which it was returned to 75% A, 25% B over 5 min, then held for 10 min. The 
absorbance was measured at 365 nm with an ultraviolet detector (L-7400 Lachrom, Merck, Germany). 
The retention times of AFB1-8,9-epoxide-GSH conjugate, AFQ1, AFM1, AFG1 and AFB1 were 9.15, 
14.05, 16.3, 19.85 and 21.60 minutes, respectively. This method does not separate the AFB1-8,9-endo- 
and –exo-epoxide stereoisomers. The standard curves were linear from 50 to 20000 pmol for AFBO 
and from 25 to 20000 pmol for AFB1. 
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3.2.5 LC-MS/MS analysis 
 
3.2.5.1 Tacrolimus 
An online-extraction method with a column switching technique combined with analytical liquid 
chromatography and electrospray-tandem-mass-spectrometry was used to quantify 13-O-
demethyltacrolimus. The supernatants obtained from microsomal incubations were injected with a 
series 200 auto-injector (Perkin Elmer). The extraction cartridge used was a security guard C18 4.0 x 
3.0 mm (Phenomenex) and the analytical column was a Nucleosil 250 x 2.1 mm, 5 µm, 100 Å, C18 
reversed phase column (particles of silica with octadecyl derivative, MZ-Analysentechnik) maintained 
at 65°C with a Du Pont column oven. The sample was introduced onto the extraction column at a flow 
rate of 1500 µl/min with deionized water (solvent A) for 0.5 min. After switching the diverter valve, 
analytes were eluted at a flow rate of 500 µL/min onto the analytical column with the following 
stepwise elution protocol: 0.5 to 3 min 65% solvent B (0.01g/L formic acid/2 mmol/L ammonium 
acetate in methanol), 3 to 4 min 75% B, 4 to 6 min 80% B, 6 to 9.5 min 100% B. The extraction 
column was then re-equilibrated with solvent A for 0.5 min at 1500 µL/min before starting the next 
injection. An API 2000 triple stage quadrupole instrument was used for quantification in the positive 
ion mode. Multiple reaction monitoring (MRM) with argon as collision gas and the following mass-
transitions (ammonium adducts) were used for quantification: 13-O-demethyltacrolimus m/z 
807.5/754.5, ascomycin m/z 809.5/756.5. Peak areas for 13-O-demethyltacrolimus were linear from 
0.5 to 5 µg/l.  
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3.3  Data analysis 
 
3.3.1 Software 
Table 5 Computer programs applied 
Software Application Source 
Excel 2000 (Microsoft Office) Correlation studies 
Linear regression 
Lineweaver-Burk plot (Km, Vmax) 
Microsoft, Redmont, WA, USA 
SigmaPlot 8.0 Nonlinear regression Chicago, IL, USA 
SPSS 12.0 Parametrical analysis 
Nonparametrical analysis 
Chicago, IL, USA 
Sequence Detection Software Version 2.1 Applied Biosystems, Foster city, 
USA 
HPLC Integration software D-7000 HPLC-system manager Merck, Darmstadt, Germany 
AIDA software  Signal quantification Raytest, Straubenhardt, 
Germany 
Quantity One Software Version 4.2.1 Biorad, Hercules (CA, USA) 
 
Table 6 Electronic Databases 
Database / Website URL 
Directory of P450-Containing Systems http://www.icgeb.trieste.it 
Cytochrome P450 Allele Nomenclature http://www.imm.ki.se/cypalleles/ 
Drugs Metabolized by Cytochrome P450 http://www.georgetown.edu/departments/ 
pharmacology/clinlist.html 
Pubmed (NIH) http://www.ncbi.nlm.nih.gov/entrez/query.fcgi 
 
3.3.2 Enzyme kinetic data analysis 
The enzyme kinetic parameters (Km, Vmax) were determined either by nonlinear regression analysis 
(SigmaPlot 8.0; SPSS) for the tacrolimus- and AFB1-projects and by linear regression analysis (Excel 
2000 Microsoft, Redmond, WA, USA) for the testosterone-project based on the following equations 
(Segel, 1975): 
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3.3.3 Calculation of relative contributions of the individual P450s 
The relative contribution of each P450 isoform (i) to the overall rate of product (6ß-
hydroxytestosterone, 13-O-demethyltacrolimus, AFB1-8,9-epoxide) formation (fi) was predicted as a 
function of substrate concentration (S), using the relative hepatic abundance (Ai) of each recombinant 
CYP3A, as determined by quantitative Western-blotting using isozyme-specific antibodies, and the 
reaction velocity Vi(S) based on the recombinant enzyme kinetic parameters (Km, Vmax) determined for 
each enzyme (Venkatakrishnan et al., 2000): 
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3.3.4 Prediction of pharmacokinetic clearance 
The kinetic parameters of baculovirus-expressed isoforms were used to estimate the in vitro intrinsic 
clearance of tacrolimus to 13-O-demethyltacrolimus. The intrinsic clearance was calculated as the 
Vmax/Km ratio (Houston, 1994). The net in vitro human liver microsomal intrinsic clearance was 
calculated for each CYP isoform, weighted by their respective baculovirus relative activity factor 
estimates, as defined previously (Venkatakrishnan et al., 2001). This was then scaled up to in vivo 
intrinsic clearance using previously published values of scaling factors: 50 mg of microsomal protein 
per gram of liver, and 20 g liver per kilogram of body weight (Carlile et al., 1999). The resulting 
estimated intrinsic clearance of tacrolimus via 13-O-demethylation (CL’int ) was used in conjunction 
with estimates of human hepatic blood flow (Q, 20 mL/min/Kg) and the free fraction of tacrolimus in 
human plasma (fu, 0.01) (Iwasaki et al., 1996) to predict intravenous clearance via 13-O-
demethylation. This was done according to the well-stirred (CLp_1) and parallel-tube models (CLp_2) 
(Obach et al., 1997; Obach, 1999) and the respective following equations (Wilkinson and Shand, 
1975; Pang and Rowland, 1977c; Pang and Rowland, 1977b; Pang and Rowland, 1977a): 
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3.3.5 Statistical analysis 
The significance of differences in values between different groups was assessed by the T-test. The 
significance of differences in predicted clearance values between different groups was assessed using 
the Mann-Whitney U Test. The association between two variables was assessed using the Spearman 
rank test in the case of nonparametric data or by the Pearson correlation coefficient (SPSS 12.0) in the 
case of Gaussian-distributed data. Multiple correlations were also calculated using Excel 2000 
(Microsoft, Redmond, WA, USA). 
 
3.4  Method validation 
 
3.4.1 Incubation 
 
3.4.1.1 Solubility 
All investigated substances were dissolved in the buffer under the concentration ranges used. Control 
experiments detected >90% of the substrates (testosterone, tacrolimus and aflatoxin B1) in the buffer 
following incubation at 37°C. 
 
3.4.2 HPLC and LC-MS/MS analysis 
 
3.4.2.1 Limit of detection (limit of quantification) 
The limit of detection, the smallest amount of unknown that can reliably be detected was calculated as 
the amount of analyte, which produced a response that was three times larger than the standard 
deviation of the instrumental noise level. The limit of quantification, the smallest amount of unknown 
that can be identified and quantitatively measured was calculated as the amount of analyte measured 
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with accuracy between 80% and 120%, and with a precision not exceeding 20%. The detection 
(quantification) limit was 20 (50) pmol and 15 (40) pmol of testosterone and 6ß-hydroxytestosterone, 
respectively. The limit of detection (quantification) was 25 (50) and 10 (25) pmol of AFBO and 
AFB1, respectively. The limit of detection (quantification) for tacrolimus and 13-O-
demethyltacrolimus was 0.1 (0.25) µg/l. 
 
3.4.2.2 Intra-day variability (inter-day variability) 
The intra-assay coefficient (inter-assay coefficient) was determined by measuring the formation of the 
produced targeted metabolite in a series of n (ranging from 10 to 20) identical incubates on the same 
day (different days) using aliquots of the same HLM lot. 
The intra-day coefficient of variation for the formation of 6ß-hydroxytestosterone was 12.4%. The 
inter-day coefficient of variation for the formation of 6ß-hydroxyestosterone was 11.8%. The intra-day 
coefficient of variation for the formation of AFBO was 5.09%. The inter-day coefficient formation of 
13-O-demethyltacrolimus was 2.7%. The inter-day coefficient of variation for the formation of AFBO 
was 14.8%. The intra-day coefficient of variation for the formation of 13-O-demethyltacrolimus was 
7%. 
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4  RESULTS 
 
4.1  Determinants of CYP3A5 activity in vitro 
It is still disputed whether CYP3A5 activity is similar to or lower than that of CYP3A4 under in vitro 
and in vivo conditions. The activities of CYP3A isozymes had been shown previously to be affected 
by several chemicals and proteins, but the optimal conditions and the existence of isozyme-specific 
differences among CYP3A are still a matter of debate. Therefore, we assessed to investigate the 
optimal conditions of the in vitro activity of CYP3A5 compared to that of CYP3A4 using testosterone 
as a model substrate. 
Divalent cations such as Ca2+ and Mg2+ at concentrations ranging from 5 to 50 mM have been 
previously shown to affect the in vitro activity of CYP3A4 (Yamazaki et al., 1995; Maenpaa et al., 
1998). In this work, 25 mM of either Ca2+ or Mg2+ were used to investigate their role on the activity of 
baculovirus-expressed (BE) CYP3A5/OR in vitro compared to that of CYP3A4/OR. The 
measurements were conducted at 200 µM testosterone, which is approximately double the Km value 
of this reaction catalyzed by CYP3A4 and CYP3A5. The results are depicted in figure 7. The addition 
of CaCl2 to a final concentration of 25 mM reduced the activity of either BE CYP3A by 70-100%. On 
the other hand, 25 mM Mg2+ halved the activity of BE CYP3A4 and CYP3A5 
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Fig. 7 Effect of Ca2+ and Mg2+ on the activities of baculovirus-expressed (BE) CYP3A4 and CYP3A5. 
The y axis represents the velocity of testosterone 6ß-hydroxylation at 200 µM testosterone. Slash (/) 
indicates co-expression (with OR) and “+” supplementation by addition of separately expressed 
protein (b5 as cytochrome b5). Each bar represents the mean of two experiments carried out in 
triplicate. Each error bar represents the standard deviation of experiments carried out in triplicate. 
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To determine whether the co-expressed OR in commercially available BE CYP3A/OR is sufficient or 
saturated, the effect of purified OR on the activity of BE CYP3A4/OR and CYP3A5/OR (slash 
indicates co-expression) were investigated. Only a concentration-dependent decrease of the rate of 6ß-
hydroxytestosterone formation by either CYP enzyme was observed, indicating that the coexpressed 
preparations contained saturating amounts of OR (Fig. 8). The same BE CYP3A4/OR and 
CYP3A5/OR were used to investigate the effect of cytochrome b5, by adding increasing amounts of 
BE b5/OR (i.e. b5 co-expressed with OR). This gradually increased the testosterone hydroxylation 
activity of CYP3A4/OR until a plateau of activation (4-fold) was reached at a 10-fold excess of 
cytochrome b5/OR. The activity of CYP3A5/OR increased 3-fold upon addition of b5/OR and the 
maximum was seen at a ratio of CYP3A5/OR to b5/OR of 1:10 (Fig. 9). These increases were in all 
likelihood caused by b5 and not by the co-expressed OR, since, as described above, the addition of 
purified OR alone decreased the activity of CYP3A4/OR and of CYP3A5/OR. This is also supported 
by the effect of purified b5, which increased the activities of CYP3A4/OR or CYP3A5/OR 3-4-fold 
(Fig. 10). Whereas the magnitude of the effect was similar for purified b5 and OR/b5, purified b5 
achieved its maximal effect at lower ratios to P450/OR than did OR/b5. 
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Fig. 8 Effect of OR ratio on the activities of baculovirus-expressed (BE) CYP3A4/OR (black bars) and 
of CYP3A5/OR (white bars). The y axis represents the velocity of testosterone 6ß-hydroxylation at 
200 µM testosterone. Each bar represents the mean of two experiments carried out in duplicate. Each 
error bar represents the standard deviation of two experiments carried out in duplicate. The ratios of 
CYP3A/OR to OR are given in parentheses. 
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Fig. 9 Effect of OR/b5 on the activities of baculovirus-expressed (BE) CYP3A4/OR (black bars) and 
of CYP3A5/OR (white bars). The y axis represents the velocity of testosterone 6ß-hydroxylation at 
200 µM testosterone. Each bar represents the mean of two experiments carried out in duplicate. Each 
error bar represents the standard deviation of two experiments carried out in duplicate. The ratios of 
the co-expressed CYP3A/OR to OR/b5 are given in parentheses 
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Fig. 10 Effect of b5 on the activities of baculovirus-expressed (BE) CYP3A4/OR (black bars) and 
CYP3A5/OR (white bars). The y axis represents the velocity of testosterone 6ß-hydroxylation at 200 
µM testosterone. Each bar represents the mean of two experiments carried out in duplicate. Each error 
bar represents the standard deviation of two experiments carried out in duplicate. The ratios of the co-
expressed CYP3A/OR to b5 are given in parentheses 
 
In addition to b5 and OR, CYP3A4 and CYP3A5 activities could be influenced by some other, 
unknown proteins. To test for their presence, we supplemented CYP3A4/OR/b5 and CYP3A5/OR+b5 
(i.e. CYP3A5/OR supplemented by b5 at a ratio of 1:1) by HLM. In either case, the activities of the 
respective P450 and HLM were additive. In contrast, there was a synergy between the activities of 
CYP3A5/OR and HLM. In all likelihood, this latter effect was caused by supplementation of b5 by 
HLM (Fig. 11). 
 45
 
Results 
 
0 100 200 300 400
HLM
3A5/OR+b5 (1:1)
3A5/OR+b5 (1:1) + HLM
3A4/OR/b5
HLM+3A4/OR/b5
3A5/OR
HLM+3A5/OR
% increase in 6ß-hydroxytestosterone formation
Fig. 11 Effect of the baculovirus-expressed (BE) CYP3A4 and CYP3A5 on 6ß hydroxytestosterone 
production by pooled human liver microsomes. Each bar represents the mean of two experiments 
carried out in duplicate. The testosterone concentration was set at 200 µM. The data are peak area of 
6ß-hydroxytestosterone expressed in %, with that measured for pooled human liver microsomes 
(HLM) taken as 100%. The corresponding values for HLM, 3A5/OR +b5, HLM + 3A5/OR +b5, 
3A4/OR/b5, HLM + 3A4/OR/b5, 3A5/OR and HLM + 3A5/OR are 100%, 152.5%, 250%, 256.5%, 
361.5%, 23.30% and 226.5%, respectively. As shown in the figure, in contrast to others, only the 
addition of 3A5/OR to HLM resulted to a synergy (23.3% + 100% →226.5%), which is caused by the 
presence of cytochrome b5 in HLM. 
 
Next we compared the specific activities of CYP3A4 and CYP3A5 under optimal conditions. In the 
absence of b5, the specific activities of CYP3A4 and CYP3A5 were nearly identical (1.71±0.25 vs. 
1.63±0.14 pmol/pmol CYP/min) (Fig.12). The molar ratio of BE CYP3A4/OR and CYP3A5/OR to b5 
was 1:1. Upon supplementation with b5, the activities of BE CYP3A4/OR and CYP3A5/OR 
supplemented by b5 were higher, but again nearly identical (7.52±0.35 vs. 7.00±1.48 pmol/pmol 
CYP/min) (Fig.12). The method of b5 supplementation was a major determinant of activity, as 
demonstrated for CYP3A4. The supplementation of b5 via co-expression with CYP3A4 and OR 
(CYP3A4/OR/b5) resulted in a much higher activity than the addition to CYP3A4/OR of an optimal 
amount of b5 (49.2±0.37 vs. 7.52±0.35 pmol/pmol CYP/min) (Fig.12). 
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Fig. 12 Comparison of the testosterone 6ß-hydroxylase activity of CYP3A4 with that of CYP3A5 in 
the presence and absence of b5. Slash indicates co-expression and “+” supplementation by addition of 
separately expressed protein. The y axis represents the velocity of testosterone 6ß-hydroxylation at 200 
µM testosterone. Each bar represents the mean of three experiments carried out in duplicate. Each 
error bar represents the standard deviation of three experiments carried out in duplicate. The ratio of 
BE CYP3A/OR to b5 was 1:1 
 
4.2  Contribution of CYP3A5 to the hepatic 6ß-hydroxylation of 
testosterone 
The specificity of 6ß testosterone hydroxylation as a marker of CYP3A was tested in microsomes 
from baculovirus cell lines expressing various individual CYP isozymes (Fig. 13). At 200 µM 
testosterone, the 6ß-hydroxylase activity of CYP1A1 was 1/3 of that of CYP3A4 and CYP3A5. All 
other CYPs tested showed low (CYP3A7, 0.72 pmol/pmol CYP/min; CYP1A2, 0.11 pmol/pmol 
CYP/min; CYP1B1, 0.57 pmol/pmol CYP/min; CYP2C19, 0.0265 pmol/pmol CYP/min) or no 
detectable 6ß testosterone hydroxylation activity (CYP2A6, CYP2B6, CYP2C9). The enzyme kinetic 
parameters (Vmax, Km) of testosterone 6ß-hydroxylation mediated by CYP3A4 and CYP3A5 are given 
in Table 7. Furthermore, we investigated the share of 6ß hydroxylation of testosterone catalyzed in 
HLM by CYP3A using an antibody, which inhibits selectively CYP3A4 and CYP3A5. A maximal 
inhibition of 85% was observed at a ratio of 10 pmol CYP to 100 µg antibody (Fig. 14).  
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Table 7 Enzyme kinetic parameters for testosterone 6ß-hydroxylation catalyzed by BE CYP3A4 and 
CYP3A5. The testosterone concentration range varied from 50 to 400 µM. The baculovirus-expressed 
enzymes were either co-expressed with b5 or supplemented with cytochrome b5. Each value 
represents the mean of two experiments carried out in duplicate. The ratio of BE CYP3A/OR to b5 
was 1:1. 
 
Enzyme kinetic parameters Baculovirus-Expressed Enzyme 
Systems 
Km  (µM) Vmax (pmol/pmol CYP/min) 
CYP3A4/OR/b5 
CYP3A5/OR 
42.94 
170.5 
35.25 
2.67 
CYP3A4/OR + b5 
CYP3A5/OR + b5 
128.8 
113.3 
14.5 
13.1 
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Fig. 13 Rate of 6ß-hydroxylation formation by baculovirus-expressed (BE) CYP3A4 and CYP3A5. 
The testosterone concentration was set at 200 µM. Each bar represents the mean of two experiments 
carried out in duplicate. Each error bar represents the standard deviation of two experiments carried 
out in duplicate All enzymes were either co-expressed with cytochrome b5 (b5) or were supplemented 
with b5 (+cyt.b5). The corresponding ratios of P450/OR to b5 were 1:1.  
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The variability of 6ß hydroxylation of testosterone was investigated in a bank of 47 liver samples 
obtained from Caucasians. The in vitro kinetic parameters of the reaction were determined at 50 µM, 
200 µM and 400 µM testosterone concentrations. There was a 28-fold variability in the Vmax values, 
which ranged from 346 to 9780 pmol/mg/min (median value 3336 pmol/mg/ min) (Table 8). The Vmax 
and Km mean values were 3387 pmol /mg/min and 90 µM, respectively. The Vmax/Km values varied 
38-fold. 
Fig. 14 Immunoinhibition of 6ß-hydroxytestosterone formation by HLM and Baculovirus-Expressed 
(BE) CYP3A4 and CYP3A5. Testosterone concentration was set at 200 µM. Each bar represents the 
mean of two experiments carried out in duplicate. Each error bar represents the standard deviation of 
two experiments carried out in duplicate. CYP3A4 and CYP3A5 were supplemented with b5. The 
ratio of BE CYP/OR to b5 was 1:1. 
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Table 8 Summary statistics of 6ß-hydroxylation of testosterone and of the expression of CYP3A proteins and of CYP3A and CYP1A1 mRNAs in 47 Caucasian 
livers.  
Liver 
Samples 
Summary 
Statistics 
Vmax  Km  Vmax / Km CYP3A5 
protein 
CYP3A4 
protein   
CYP3A4 
mRNA  
CYP3A5 
mRNA  
CYP3A7 
mRNA  
CYP3A43 
mRNA  
CYP1A1 
mRNA  
  pmol/mg/min µM µl/min/mg pmol/mg x 1000 copies/ng of total RNA 
Mean ± 
SD 
2976 ± 2787 92 ± 
43 
29 ± 20 13 ± 3 64 ± 75 391 ± 118 36 ± 18 11 ± 11 1 ± 0.39 0.77 ± 0.61 
Median 
values 
2406 104 38.5 14.8 20.7 407 25 10 0.88 0.77 
Range 346 –6220 34 – 
138 
3 – 51 9-16 11.5 – 
188 
248 – 526 21– 62 1.8 – 30 0.72 – 1.67 0.009 – 0.15 
3A5 
*1/*3 
Livers 
n = 6 
Variability 
(fold) 
18 4 15 1.78 16 2 3 17 2.3 162 
Mean ± 
SD 
3798 ± 2412 87.5 ± 
36 
45 ± 25 0 81 ± 77 451 ± 270 6 ± 8300 10 ± 15 1.38 ± 1.24 0.47 ± 0.53 
Median 
values 
3466 86 37 0 50.7 380 4.26 2.9 0.79 0.29 
Range 400 –9781 14 – 
164 
5.4 – 115 0 4 – 375 695 – 170 2 – 10.5 0.18 – 56 0.14 – 5 0.007 – 2 
3A5 
*3/*3 
Livers  
n = 41 
Variability 
(fold) 
25 12 21 0 94 17 5 313 28 305 
 
Results 
The Vmax values were compared with the expression of the CYP3A and CYP1A1 genes, the protein 
products of which were found above to contribute significantly to 6ß hydroxylation of testosterone. 
The variabilities in the expression of CYP3A mRNA species and of the CYP3A4 and CYP3A5 
proteins and the respective average values for the 47 livers investigated here are given in Table 8. The 
expression of CYP1A1 mRNA was low and varied 305-fold in the sample set (Table 8). The only 
significant correlations were found for CYP3A4 mRNA (r=0.51, p<0.001) and CYP3A4 protein 
(r=0.66, p<0.001) (Table 9, Fig. 15A, C). The correlation between Vmax and CYP3A5 mRNA in the 
six livers from CYP3A5*1 heterozygotes was higher than that for CYP3A5*3 homozygotes (0.21 vs. 
0.02), but it was not significant (Table 9, Fig.15B). The correlation between CYP3A5 protein and Vmax 
in CYP3A5*1/*3 livers was 0.22 (Table 9, Fig.15D). The corresponding value for CYP3A5*3/*3 
livers could not be calculated, because the protein expression was below the limit of quantification. 
Combining CYP3A4 mRNA expression with the expression of other CYP3A mRNA species did not 
increase the degree of correlation (Table 9).  
Table 9 Correlations between Vmax of 6ß-hydroxylation of testosterone and expression of selected 
P450 mRNAs and protein species. 
 
Vmax versus Correlation coefficient (r) Number of samples P values 
CYP3A4 protein 0.66 47 < 0.001 
CYP3A4 mRNA 0.51 47 < 0.001 
CYP3A5 mRNA: all livers 0.064 47 0.33 
       CYP3A5 mRNA: *1/*3 livers 0.21 6 0.34 
       CYP3A5mRNA: *3/*3 livers 0.02 41 0.45 
       CYP3A5 protein: *1/*3 livers 0.22 6 0.64 
CYP3A7 mRNA 0.12 47 0.21 
CYP3A43 mRNA 0.25 47 0.044 
CYP3A4 plus CYP3A5 mRNA 0.50 47 < 0.001 
Total CYP3A mRNA 0.50 47 < 0.001 
CYP1A1 mRNA 0.17 47 0.12 
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Fig. 15 Correlations between Vmax of 6ß hydroxylation of testosterone and the expression of CYP3A4 
mRNA (A), CYP3A5 mRNA (B), CYP3A4 protein (C), and CYP3A5 protein. (D) 
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The contribution of CYP3A5 to testosterone 6ß-hydroxylation was investigated in 5 CYP3A5*1/*3 
livers using the relative hepatic abundance approach. At 200 µM testosterone, CYP3A5 accounted for 
5%, 15%, 34%, 41% and 54% of the reaction in these livers (Table 10). The relatively high 
contribution of CYP3A5 in the latter three livers was caused by low expression of CYP3A4 (<21 
pmol/mg protein).  
Table 10. Relative contribution of CYP3A5 to testosterone 6ß-hydroxylation in 47 Caucasian liver 
samples. 
 
selected HLM 
(n=47) 
Vmax 
(pmol/mg/min) 
CYP3A4 
(pmol/mg) 
CYP3A5 
(pmol/mg) 
CYP3A4 
contribution (%) 
CYP3A5 
contribution (%) 
IKP148-
006_3A5*1/*3 
346.2 11.5 14.8 46.06 53.94 
IKP148-
007_3A5*1/*3 
374.1 15.9 9 66 34 
IKP148-
041_3A5*1/*3 
6220.1 188 11.7 94.64 5.36 
IKP148-
061_3A5*1/*3 
2406.6 20.7 15.5 59.47 40.53 
IKP148-
085_3A5*1/*3 
5536.7 85 16 85.38 14.62 
IKP148-
livers_3A5*3/
*3 (n=42) 
399.7-9780.7 4.1-375 N.D. 100 0 
 
4.3  Contribution of CYP3A5 to the hepatic metabolism of tacrolimus 
Previous investigations using human liver microsomes have indicated that CYP3A plays an important 
role in the metabolism of tacrolimus, the major primary metabolite being 13-O-demethyltacrolimus 
(Sattler et al., 1992; Karanam et al., 1994; Shiraga et al., 1994). Patients with high concentrations of 
CYP3A5 require higher doses of tacrolimus ((Macphee et al., 2002; Hesselink et al., 2003; Thervet et 
al., 2003; Zheng et al., 2003; Haufroid et al., 2004; Zheng et al., 2004; Macphee et al., 2005; Thervet 
et al., 2005). Better understanding of the role of CYP3A5 in tacrolimus disposition has been hampered 
by the paucity of in vitro data on tacrolimus metabolism by CYP3A5. Indeed, although tacrolimus 
metabolism to 13-O-demethyltacrolimus by CYP3A5 has been demonstrated (Bader et al., 2000), a 
detailed investigation on the kinetics of this reaction is lacking. Particularly informative would be a 
direct comparison with CYP3A4. Therefore, the relative contributions of CYP3A5 and CYP3A4 to the 
formation of the main tacrolimus metabolite (13-O-demethyltacrolimus) was set out to be assessed 
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using cDNA-expressed enzymes and a bank of human liver microsomes derived from low and high 
CYP3A5 expressors. 
The specificity of 13-O-demethylation of tacrolimus was tested in microsomes from baculovirus cell 
lines expressing various individual CYP isozymes. At a concentration of 5 µM tacrolimus, CYP3A4 
and CYP3A5 were the predominant CYP enzymes responsible for 13-O demethylation of tacrolimus 
and their corresponding catalytic activities were 0.54 and 0.79 pmol/CYP/min, respectively. CYP3A7 
also exhibited some catalytic activity, but was 10-fold lower (0.065 pmol/pmol CYP/min). All other 
CYP tested showed extremely low 13-O demethylation activity (CYP1A2, 0.00058 pmol/pmol 
CYP/min; CYP2A6, 0.0014 pmol/pmol CYP/min; CYP1B1, 0.00084 pmol/pmol CYP/min; CYP2B6, 
0.00064 pmol/pmol CYP/min; CYP2C8, 0.00084 pmol/pmol CYP/min; and CYP2C9, 0.00092 
pmol/pmol CYP/min). Other metabolites, such as 13,15-O-demethyltacrolimus and 13,31-O-
demethyltacrolimus were also detected, but their levels were 10-20 times lower than those of 13-0-
demethyltacrolimus (Fig. 16). An example of a LC-MS/MS extracted ion peak chromatogram of 13-
O-demethyltacrolimus, 15-O-demethyltacrolimus, 31-O-demethyltacrolimus, 13,31-O-
didemethyltacrolimus and 13,15-O-didemethyltacrolimus is shown in Fig. 16 
 
Panel A. 
 
Panel B. 
 
Fig. 16 LC-MS/MS extracted ion chromatograms of 100 µl supernatants of microsomal incubates of 
13-O-demethyltacrolimus (1, Panel A), 15-O-demethyltacrolimus (2, Panel A), 31-O-
demethyltacrolimus (3, Panel A), 13,31-O-didemethyltacrolimus (4, Panel B) and 13,15-O-
didemethyltacrolimus (5, Panel B). 
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Next, the enzyme kinetic parameters for 13-O-demethylation of tacrolimus catalyzed by baculovirus-
expressed CYP3A4 and CYP3A5 were determined. The tacrolimus concentration range varied from 0 
to 12.5 µmol/L. The calculated Km and Vmax values using nonlinear regression analysis and fitting the 
data to the Michaelis-Menten equation were 1.5 µmol/L and 0.72 pmol/pmol P450/min for CYP3A4 
(Fig. 17A), and 1.4 µmol/L and 1.1 pmol/pmol P450/min for CYP3A5 (Fig. 17B). The corresponding 
Vmax/Km ratios were 0.48 and 0.79 for CYP3A4 and CYP3A5, respectively. 
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Fig. 17 Kinetic plots of 13-O-demethylation of tacrolimus by cDNA-expressed CYP3A4 (A) and 
CYP3A5 (B). CYP3A4 and CYP3A5 were supplemented with cytochrome b5. The ratio of 
CYP3A/OR to b5 was 1:1 
 
Next, the tacrolimus 13-O-demethylation activity was investigated in a bank of 15 human liver 
samples, including 12 high expressors (homozygous or heterozygous carriers of CYP3A5*1) and 3 
low expressors (homozygous carriers of CYP3A5*3) of CYP3A5. The relevant data are given in Table 
11. There was an almost 19-fold variation in the Vmax of tacrolimus 13-O demethylation with values 
ranging from 199.3 pmol /mg/min to 3746.7 pmol /mg x min (median: 564.8 pmol /mg/min) (Table 
11). Less variation was observed in the respective Km values (median: Km 0.74 µmol/L; range 0.38 – 
1.20 µmol/L).  
Subsequently , we compared the Vmax values obtained for the individual HLM with the corresponding 
protein contents of CYP3A4 and CYP3A5. The correlation coefficient (r) between Vmax of tacrolimus 
13-O demethylation and CYP3A5 protein was 0.65 (p=0.008) and was thus higher than that for Vmax 
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and CYP3A4 protein 0.49 (p=0.09) (Fig. 18). We also observed a good correlation (r=0.64, (p=0.01), 
Fig. 18) between Vmax values of tacrolimus 13-O demethylation and those of testosterone 6ß-
hydroxylation (supplied in the package insert for each HLM). Since the latter reaction is a marker of 
the CYP3A activity (Kamdem et al., 2004), this result further confirms that tacrolimus is mostly 
metabolized by CYP3A. The data in Fig. 18 were also analyzed after the omission of the outlier with 
the particularly high Vmax value. Significant correlations were still observed between Vmax and either 
CYP3A5 protein (r=0.56, p=0.03) or testosterone 6ß-hydroxylation (r=0.57, p=0.03). No significant 
correlation was found between Vmax and CYP3A4 protein (r=0.35, p=0.265) after exclusion of the 
outlier. No correlation was found between CYP3A4 and CYP3A5 protein in these samples (Fig. 18). 
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Table 11 Kinetic constants for the conversion of tacrolimus to 13-O-demethyl tacrolimus and estimated intrinsic tacrolimus clearances in a bank of human liver 
samples 
Materials 
Vmax 
(pmol/mg/min) 
Km 
(µmol/L)
Vmax/Km 
(µl/mg/min)
CLp_1 
(ml/min/kg ) 
CLp_2 
(ml/min/kg) 
CYP3A4 
Protein1 
(pmol/mg)
CYP3A5 
Protein1 
(pmol/mg) Sex1
Age1 
(years)
T-6ß-OH Activity1
(pmol/mg/min) 
CYP3A5 LE livers (n=3) 
HG03 320.7 0.43 745.81 3.63 3.98 95 0.9 F 30 4600 
HG64 199.3 0.51 390.78 2.43 2.58 NA 1.2 M 63 1800 
HG74 336.4 1.2 280.33 3.78 4.16 NA 1.1 M 32 2600 
CYP3A5 HE livers (n=12) 
HH54 671.3 0.56 1198.75 6.35 7.44 87 8.6 F 62 4300 
HH31 3746.7 0.54 6938.33 14.44 18.51 300 14 F 51 12000 
HH47 1129.5 0.47 2403.19 8.78 10.85 62 9.3 F 53 4100 
HH91 1069.7 0.53 2018.3 8.51 10.46 46 5.7 F 55 2900 
HG95 335.8 0.74 453.78 3.77 4.15 29 6.9 F 47 760 
HH86 564.8 0.38 1486.32 5.62 6.47 83 7.6 M 57 3500 
HH3 835 0.96 869.79 7.33 8.78 76 11 M 38 6500 
HH108 448 0.86 520.93 4.74 5.33 27 11 F 27 3700 
HH89 453.8 1.1 412.55 4.78 5.39 38 11 M 33 2200 
HH48 457.7 0.85 538.47 4.81 5.43 30 9.8 M 62 1700 
HH9 943.4 0.89 1060 7.9 9.59 53 12 M 51 5300 
HH1 1122.9 1.1 1020.82 8.75 10.81 110 12 F 31 8000 
Summary Statistics for all livers (n=15) 
Median 564.80 0.74 869.79 5.62 6.47 62.00 9.30  51 3700 
Range 199.3 -3746.7 
0.38 - 
1.12 
280.33 –
6938.33 2.43 – 14.4 2.58 – 18.51 27 – 300 0.9 – 14  27 – 63 760 – 12000 
Summary Statistics for CYP3A5 HE livers (n=12) 
Median 753.15 0.79 1040.41 6.84 8.11 57.5 10.4  51 3900 
Range 335.8 – 3746.7 0.38 –1.1
412.55 –
6938.33 3.77 –14.44 4.15 –18.51 27 - 300 5.7 - 14  27 - 62 760 – 12000 
1data supplied by BD Gentest 
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Fig. 18 Correlations between Vmax of 13-O demethylation of tacrolimus and (A) CYP3A4 protein, (B) 
CYP3A5 protein, (C) 6ß-hydroxylation of testosterone. (D) Correlation between CYP3A4 protein and 
CYP3A5 protein. 
 
The contribution of CYP3A5 to tacrolimus 13-O demethylation was determined in the liver bank using 
the relative hepatic abundance approach as described in Materials and Methods (section 3.3.3, 
calculation of relative contribution), assuming that the enzyme kinetic constants determined for the 
individual recombinant CYP3A isozymes were also valid for the hepatic liver microsomes. At 5 
µmol/L tacrolimus, a concentration within the range measured in hepatic tissue in vivo, CYP3A5 
accounted for 1.5% - 40 % of 13-O demethylation of tacrolimus. No significant association was found 
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between the contribution of CYP3A5 to 13-O-demethylation and the amount of CYP3A5 protein (Fig. 
19A, r = 0.20, p = 0.51), but there was an inverse association with the amount of the CYP3A4 protein 
(Fig. 19B, r = 0.90, p<0.0001). Similar results were obtained at 0.5 and 50 µmol/L tacrolimus. 
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Fig. 19 Correlation between the relative contribution of CYP3A5 to the 13-O demethylation of 
tacrolimus and (A) CYP3A5 protein and (B) CYP3A4 protein in a liver bank (n=13, the 2 livers with 
no CYP3A4 protein data were excluded from the analysis). The relative contribution has been 
calculated based on the hepatic abundance approach as described in Materials and Methods. The 
tacrolimus concentration was 5 µmol/L.  
 
Based on the relative activity factor approach (Venkatakrishnan et al., 2001) and using the parallel 
tube model , the predicted tacrolimus 13-O-demethylation clearance values (CLp2) in CYP3A5 high 
and low expressers livers were on average 8.60 ml/min/kg and 3.57 ml/min/kg of body weight, 
respectively (p=0.0088, Mann-Whitney U test) (Fig. 20). The predicted tacrolimus 13-O 
demethylation clearance values (CLp1) using the well-stirred model were also calculated and they 
were similar to the CLp2 values (Table 11). 
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Fig. 20 Prediction of tacrolimus pharmacokinetic clearance of human liver samples using the parallel 
tube model as described in Materials and Methods. The horizontal line indicates the mean value of 
high (HE) and low CYP3A5 expressers (LE). 
 
4.4  Contribution of CYP3A4, CYP3A5, CYP3A7 and CYP1A2 to the 
hepatic production of aflatoxin B1-8,9-epoxide 
Previous investigations showed that CYP3A and CYP1A2 are the major enzymes involved in the 
metabolism of AFB1 in adult human liver microsomes (Forrester et al., 1990; Ramsdell et al., 1991; 
Ueng et al., 1995; Patterson et al., 1999). CYP3A4 produces predominantly AFB1-8,9-exo-epoxide 
and AFQ1, whilst CYP1A2 leads to the formation of AFB1-8,9-exo and endo-epoxide, and of AFM1. 
CYP3A5 metabolizes AFB1 mainly to the exo-epoxide (Wang et al., 1998), and so does CYP3A7 
(Kitada et al., 1989; Kamataki et al., 1995; Yamada et al., 1998). However, there is still some 
discrepancy regarding the relative importance of CYP1A2 and CYP3A isoforms in human AFB1-8,9-
exo-epoxide (the most carcinogenic and toxic AFB1 metabolite) formation. Therefore, the metabolism 
of AFB1 in a bank of liver samples phenotyped for the expression of CYP3A4, CYP3A5, and 
CYP1A2 was investigated. This was followed by a calculation of the relative contributions of the 
CYPs to AFBO formation in human livers at AFB1 concentrations encountered in exposed 
individuals. 
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Representative HPLC chromatograms of AFB1 metabolism by baculovirus-expressed CYP3A5, 
CYP3A4, CYP3A7, and CYP1A2 are shown in Fig. 21 and the enzyme kinetic parameters describing 
the formation of the metabolites detected are given in Table 12. Within the AFB1 concentration range 
investigated (25 to 500 µM), CYP3A5 produced exclusively AFBO. CYP3A4 produced AFQ1 and 
AFBO (Vmax ratio 8:1), but no AFM1. CYP3A7 had a similar profile of AFB1 metabolites as 
CYP3A4, with an AFQ1:AFBO Vmax ratio of 23:1. In contrast to CYP3A4 and CYP3A7, CYP1A2 
produced AFM1 and AFBO (Vmax ratio 2.5:1), but no AFQ1. CYP1A2 had the lowest Km values for 
AFM1 and AFBO formation. CYP3A4 showed the highest intrinsic clearance (Vmax/Km) towards 
AFBO , followed by CYP1A2, CYP3A5, and CYP3A7. CYP2A6, CYP2B6, CYP2C8 and CYP2C9 
showed no detectable production of AFB1 metabolites. 
 
Table 12 Kinetic constants for the conversion of AFB1 to AFQ1 and AFBO (AFB1-8,9-epoxide) by 
baculovirus-expressed CYP1A2, CYP3A4, CYP3A5, and CYP3A7. Each value represents the mean 
of two experiments carried out in duplicates. 
 
a Kinetic constants 1A2/OR 3A4/OR+b5 (1:1) 
3A5/OR+b5 
(1:1) 3A7/OR/b5 
Vmax AFBO  0.39 1.64 1.2 0.27 
Km AFBO  55 130 302 121 
Vmax/Km AFBO  
 0.007 0.012 0.0039 0.0022 
Vmax  AFQ1  N.D. 13.32 N.D. 6.35 
Km AFQ1 N.D. 324 N.D. 204 
Vmax/Km AFQ1 
 N.D. 0.041 N.D. 0.031 
Vmax AFM1 0.95 N.D. N.D. N.D. 
Km AFM1 29 N.D. N.D. N.D. 
Vmax/Km AFM1 
 0.032 N.D. N.D. N.D. 
 a pmol/pmol CYP/min (Vmax), µM (Km) and µl/pmol CYP/min (Vmax/Km). N.D., not detected. 
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A 
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C 
 
D 
 
E 
 
 
Fig. 21 Representative chromatograms of primary AFB1 metabolites formed by baculovirus-expressed 
CYP3A4 (A), CYP3A5 (B), CYP3A7 (C), CYP1A2 (D), and by human liver microsomes (HML, 
sample HH1 in Table 13) at 250 µM AFB1 (E). AFG1 was used as an internal standard. AFBO peak 
represents the glutathione conjugate of AFB1 8,9-epoxide. 
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AFB1 metabolism was then investigated in a set of human liver microsomes (HLMs) derived from 13 
individuals. Protein expression data for the relevant P450s in these HLMs are given in Table 13. All 
but two donors (HG64 and HG74) were CYP3A5 high expressers. There was a 2-fold variability in the 
CYP3A5 expression among high expressers, whereas the corresponding value for all 13 livers was 11-
fold. The variability in CYP3A4 expression was 4-fold and that of CYP1A2 was 16-fold. The 
correlation coefficient r between the expression of the CYP1A2 protein and the CYP1A2 activity 
marker phenacetin O-deethylase activity (Yuan et al., 2002) was 0.70 (p=0.003). CYP1A2 accounted 
on average for 2% of the total CYP content; the corresponding values for CYP3A4 and CYP3A5 were 
20 and 3%, respectively. The correlation coefficients between the expression levels of the CYP3A4 
protein versus CYP3A5 protein, CYP3A4 protein versus CYP1A2 protein, and CYP3A5 protein 
versus CYP1A2 protein were 0.18, 0.30, and 0.09, respectively (all 3 p values >0.05). 
 
The major AFB1 metabolite detected in these HLM was AFQ1 followed by AFBO (Fig. 21, last panel, 
and Table 13). AFM1 was detected in none of the liver samples. There was a 12-fold variation in the 
Vmax of the AFBO formation. The variation in Vmax of AFQ1 formation was 22-fold. There was a 
statistically significant correlation between Vmax values of AFBO and AFQ1 formation in the HLM set 
(Fig. 22). The ratio of AFQ1 and AFBO Vmax median values in HLMs (7.2:1) was almost identical to 
the corresponding ratio obtained for CYP3A4 baculovirus-expressed enzyme (8:1) given above. We 
compared the kinetic parameters for the formation of these metabolites between the recombinant 
CYP3A4 and HLM. This was done with the consideration of the CYP3A4 expression levels in HLMs 
(Table 13). The median Vmax (1.91 pmol/pmol P450/min), Km (225 µM) and Vmax/Km (0.01 µl/pmol 
P450/min) values for AFBO formation as well as median Vmax (13.74 pmol/pmol P450/min), Km (415 
µM) and Vmax/Km (0.033 µl/pmol P450/min) values for AFQ1 formation in this liver bank were very 
similar to the corresponding values measured with recombinant CYP3A4 (Table 12).  
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Table 13 Kinetic constants a for the conversion of AFB1 to AFBO and AFQ1 in a bank of microsomes derived from human liver samples 
 
Materials Vmax 
(AFBO) 
Km 
(AFBO) 
Vmax  
(AFQ1) 
Km 
(AFQ1) 
Total 
P450 
content 
3A4 
Protein 
3A5 
Protein 
1A2 
Protein 
Phenacetin 
O-deethylase 
activity 
(pmol/mg/min) 
Sex Age (years) 
CYP3A5 LE (n=2) 
HG64 477 307 3560 312 340 NA 1.2 0.27 145 M 63 
HG74 613 186 4308 450 250 NA 1.1 4.32 580 M 32 
CYP3A5 HE (n=11) 
HH54 365 102 2865 283 240 87 8.6 3.72 230 F 62 
HH47 840 414 11281 1762 260 62 9.3 2.34 360 F 53 
HH91 332 106 6925 724 340 46 5.7 3.84 390 F 55 
HG95 236 350 657 645 230 29 6.9 3.43 290 F 47 
HH86 541 163 4046 310 330 83 7.6 2.40 300 M 57 
HH3 967 267 1649 109 370 76 11 1.91 210 M 38 
HH108 384 90 1587 112 310 27 11 3.76 330 F 27 
HH89 261 125 2261 370 300 38 11 2.74 240 M 33 
HH48 261 260 1334 256 210 30 9.8 1.80 130 M 62 
HH9 782 249 8669 1098 210 53 12 4.27 660 M 51 
HH1 4633 230 16871 1207 490 110 12 2.15 400 F 31 
Summary Statistics for all livers (n=13) 
Mean 770 374 5552 685 299 58 8.24 2.84 328  47 
Median 573 225 4124 415 300 53 9.3 2.74 300  42 
Range 281-3366 104 -1553 753 - 16871 120-1937 210- 490 27 - 110 1.1 - 12 0.27-4.32 130 - 660  27 - 63 
Summary Statistics for CYP3A5 HE (n=11) 
Mean 873 214 5286 625 299 58 9.53 2.94 321.81  46.90 
Median 384 230 2865 371 300 53 9.8 2.74 300  51 
Range 236-4632 90 - 414 657-16871 109-1762 210-490 27 - 110 5.7 - 12 1.8-4.27 130 - 660  27 - 62 
a pmol/mg/min (Vmax ), µM (Km) and pmol/mg (total P450, CYP3A4, CYP3A5, and CYP1A2). 
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Fig. 22 Correlations between Vmax values of AFBO and AFQ1 formations in a panel of human liver 
microsomes 
 
These results suggested that most of AFQ1 and AFBO production was catalyzed by CYP3A4. To 
verify this, Vmax values of AFQ1 and AFBO productions measured in the individual HLM were 
compared with the expression levels of CYP3A4, CYP1A2 and CYP3A5, and with the CYP1A2 
activity marker phenacetin O-deethylase. In agreement with the dominant role of CYP3A4 in AFQ1 
production, Vmax of AFQ1 formation correlated statistically significantly with the expression of the 
CYP3A4 protein (Fig. 23A). The corresponding values for CYP3A5 (Fig. 23B) and CYP1A2 (both 
protein and phenacetin O-deethylase, Fig. 23C, D) were low and statistically insignificant, in 
agreement with the incapability of these P450s to catalyze AFQ1 (Fig. 21, Table 12). The correlation 
coefficient r was statistically significant between the CYP3A4 protein expression and Vmax of AFBO 
formation (Fig. 23A). The corresponding values for CYP3A5 (Fig. 24B) and CYP1A2 (both protein 
and phenacetin O-deethylase, Fig. 24C, D) were lower and statistically insignificant, even though both 
of these P450s are capable of AFBO production (Fig. 21, Table 12).  
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Fig. 23 Correlations between Vmax of AFQ1 formation and (A) CYP3A5 protein, (B) CYP3A4 protein, 
(C) CYP1A2 protein, and (D) phenacetin-O-deethylase activity in a panel of human liver microsomes. 
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Fig. 24 Correlations between Vmax of AFBO formation and (A) CYP3A4 protein, (B) CYP3A5 
protein, (C) CYP1A2 protein, and (D) phenacetin-O-deethylase activity in a panel of human liver 
microsomes. 
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The absence of correlations between the hepatic CYP3A5 and CYP1A2 expression level and AFBO 
production was in apparent disagreement with the considerable clearance of AFB1 to AFBO by the 
recombinant CYP3A5 and CYP1A2 (Table 12). To resolve this discrepancy, the contributions of 
CYP3A5 and of CYP1A2 to AFBO formation were calculated at an epidemiologically relevant AFBO 
concentration of 0.1 µM using a hepatic abundance model. The model takes into account both the 
kinetic parameters (Table 12) and the hepatic expression levels of CYP3A5 and CYP1A2 (Table 13). 
Under these conditions, the contribution of CYP3A5 showed an inverse, statistically significant 
correlation with the amount of CYP3A4 protein (Fig. 25; r = 0.82; p<0.001). The highest relative 
contribution of CYP3A5 to AFBO formation (15.3%) was observed in the liver HH108, which is a 
CYP3A5 high expresser with the lowest CYP3A4 expression of all livers investigated. 
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Fig. 25 Correlation between the relative contribution of CYP3A5 to AFBO formation and the 
expression of the CYP3A4 protein in a panel of human liver microsomes from CYP3A5 high 
expressers. Data calculated using a hepatic abundance model for the in vivo relevant AFB1 
concentration of 0.1 µM using kinetics and protein expression data from Tables 12 and 13.  
 
Using the same model, the relative contributions of CYP3A4, CYP3A5, CYP3A7, and CYP1A2 to the 
primary conversion of AFB1 (0.1 µM) were calculated. On average, 89% of AFB1 are converted to 
AFQ1 and 11% to AFBO (Fig. 26), but, depending on the liver, the ratio of the two metabolites may 
vary between 19:1 (95% AFQ1, 5% AFBO) and 1.7:1 (63% AFQ1 and 37% AFBO). CYP3A4 is the 
exclusive source of AFQ1, except for individuals with increased CYP3A7 expression. In the latter 
group, CYP3A7 contributes up to 22% of AFQ1. This value results from the specific clearance of 
AFB1 to AFQ1 by CYP3A7 (Table 12) and the hepatic CYP3A7 expression levels of 24-90 pmol/mg 
protein (Sim et al., 2005). AFBO is catalyzed by CYP3A4, CYP3A5, CYP1A2, and CYP3A7. A 
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majority of AFBO is contributed by CYP3A4, but its share varies, depending on the concomitant 
expression of CYP3A5 and CYP3A7. CYP3A5 may contribute between 4% and 15% of AFBO in 
CYP3A5 high expressers. The respective value for CYP3A7 high expressers is 5-7%, whereas 
CYP1A2 contributes less than 5% of AFBO. 
 
Fig. 26 Hepatic metabolism of AFB1 in CYP3A5 or CYP3A7 high expressers at a concentration of 
0.1 µM. Data calculated using a hepatic abundance model for the in vivo relevant AFB1 concentration 
of 0.1 µM using kinetics and protein expression data from Tables 11 and 12. Both the detoxification to 
AFQ1 and the oxidation to the genotoxic AFBO are catalyzed predominantly by CYP3A4. CYP3A5 
contributes between 4 and 15% of AFBO formation, depending on the concomitant expression of 
CYP3A4. The contribution of CYP3A7 to AFQ1 and AFBO formation in CYP3A7 high expressors 
(in italics) was calculated using hepatic CYP3A7 expression levels reported by Sim et al. (Sim et al., 
2005). 
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5  DISCUSSION 
5.1  Determinants of CYP3A5 activity in vitro 
It is still disputed whether CYP3A5 activity is similar to or lower than that of CYP3A4 under in vitro 
and in vivo conditions, although the substrate specificity and product regioselectivity of CYP3A4 can 
differ from that of CYP3A5. The activities of CYP3A isozymes had previously been shown to be 
affected by several chemicals and proteins, but the optimal conditions and the existence of differences 
between CYP3A4 and CYP3A5 isoforms in substrate or reaction specificity are still a matter of 
debate. Previous studies compared the metabolic capabilities of CYP3A isoforms expressed under 
different conditions either in the presence or absence of b5 (Gillam et al., 1995; Williams et al., 2002; 
Yamazaki et al., 2002; Patki et al., 2003) which hampered the interpretation of the results. 
In our hands, using baculovirus-expressed (BE) CYP3A4 and CYP3A5 enzymes, we detected the 
inhibition of the CYP3A activity by additional exogenous oxidoreductase (OR). This finding suggests 
that the BE preparations used contained an optimal, but possibly an excess of OR. In the latter case, 
the true activity of the P450 would be underestimated. Thus it is conceivable that some P450 
preparations may contain saturated amounts of OR, at least in some lots. While optimal ratio of P450 
to OR can be determined for individually expressed proteins, caution is advised for co-expressed 
proteins. The same is true for HLM, where testosterone hydroxylation activity was inhibited by either 
OR or b5. Previously, Yamazaki and colleagues demonstrated an increase of testosterone 
hydroxylation in HLM supplemented with OR (co-expressed with CYP1A2, which does not 
metabolize testosterone) (Yamazaki et al., 2002). Together, these observations suggest that the OR and 
b5 content may vary between different HLM preparations and therefore may falsify the activity levels. 
Another important parameter is the expression system used for CYP3A activity assessment. The 
isozyme-specific activity of CYP3A4 is usually considered several-fold higher than that of CYP3A5, 
although there are some exceptions to this opinion (Gillam et al., 1995). In our experiments , under 
similar expression and incubation conditions, CYP3A4 and CYP3A5 appear to exhibit similar specific 
activities. Furthermore, a co-expression of b5 has a much stronger effect on the CYP3A4 activity than 
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its addition to the incubation mixture (results, section 4.1 fig. 12). Indeed, upon addition of b5 to 
CYP3A4 or CYP3A5 co-expressed (BE) with OR, or in the absence of b5, these two P450 exhibit 
similar activities. The much higher activity of CYP3A4 is observed only in a preparation where all 
three enzymes are co-expressed (CYP3A4/OR/b5), as previously reported by Williams and colleagues 
(Williams et al., 2002). This suggests that the method of co-expression rather than the isozyme-
specific activity of CYP3A4 are responsible for this high activity. Consequently, we propose that the 
specific activities of CYP3A4 and CYP3A5 towards testosterone are similar. This may not apply to 
other substrates, in agreement with CYP3A4 and CYP3A5, Km and Vmax values strongly varying with 
substrate used (table 14, (Williams et al., 2002)). Altogether, these data indicate that comparisons of 
activities of these isozymes towards other substrates should be performed in strictly comparable 
expression systems. 
Table 14 Enzyme kinetic parameters for testosterone 6ß-hydroxylation, 13-O-demethylation of 
Tacrolimus and AFB1-8,9-epoxidation catalyzed by BE CYP3A4 and CYP3A5. The testosterone 
concentration range varied from 50 to 400 µM. The tacrolimus concentration range varied from 0 to 
12.5 µM. The AFB1 concentration range varied from 25 to 500 µM. The baculovirus-expressed 
enzymes were supplemented with cytochrome b5. The ratio of BE CYP3A/OR to b5 was 1:1. 
 
Enzyme kinetic parameters Baculovirus-Expressed 
Enzyme Systems Km  (µM) Vmax
(pmol/pmol CYP/min) 
Vmax/Km
(µl/pmol CYP/min) 
Testosterone 6ß-hydroxylation 
CYP3A4/OR + b5 
CYP3A5/OR + b5 
128.8 
113.3 
14.5 
13.1 
0.11 
0.11 
Tacrolimus 13-O-demethylation 
CYP3A4/OR + b5 
CYP3A5/OR + b5 
1.5 
1.4 
0.72 
1.1 
0.48 
0.78 
AFB1 8,9-epoxidation 
CYP3A4/OR + b5 
CYP3A5/OR + b5 
130 
302 
1.64 
1.2 
0.012 
0.0039 
 
5.2  Contribution of CYP3A5 to the hepatic 6ß-hydroxylation of 
testosterone 
The 6ß hydroxylation of testosterone is a widely used probe of CYP3A activity (Yuan et al., 2002). In 
our experiments , a majority of the activity (85%) could be inhibited by a monoclonal antibody against 
CYP3A4 and CYP3A5. Furthermore, the only enzyme capable of testosterone metabolizing with 
appreciable activity besides CYP3A4, CYP3A5 and CYP3A7 was CYP1A1. This latter enzyme is 
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usually referred to as extrahepatic. In agreement with numerous recent reports (Nishimura et al., 2002; 
Chang et al., 2003), we detect CYP1A1 in the liver, although the low transcript numbers suggest low 
levels of CYP1A1 protein. Altogether, it appears that the 6ß hydroxylation of testosterone is a fairly 
specific phenotyping probe for CYP3A. However, despite similar specific activities, the contribution 
of CYP3A4 to the hepatic clearance of testosterone is much more significant than that of CYP3A5. 
This is evidenced by the poor correlation of Vmax of testosterone 6ß hydroxylation with CYP3A5 
mRNA expression on one side, and a good correlation with CYP3A4 mRNA and protein on the other 
side. It is obvious that the higher the correlation between an enzyme’s expression and a marker 
enzymatic activity, the higher the contribution of this enzyme to this activity. Of all CYP3A genes, 
CYP3A4 is the only one that shows an appreciable and statistically significant correlation with the 
Vmax values of 6ß hydroxylation of testosterone. The correlation with CYP3A5 was poor and 
remained insignificant despite the consideration of the CYP3A5 polymorphism status. Furthermore, 
the predicted pharmacokinetic clearances of testosterone did not differ between CYP3A5*3/*3 and 
CYP3A5*1/*3 livers. The limited contribution of CYP3A5 to the hepatic testosterone 6ß 
hydroxylation activity in Caucasian liver samples is in agreement with the low share of CYP3A5 
transcripts in the CYP3A transcript pool, which is on average 2.5%-3.9% in livers irrespective of the 
CYP3A5 polymorphism status and does not exceed 10%-20% in livers carrying CYP3A5*1 alleles 
(Koch et al., 2002; Westlind-Johnsson et al., 2003). 
 
5.3  Contribution of CYP3A5 to the hepatic metabolism of tacrolimus 
Previous investigations using human liver microsomes have indicated that CYP3A4 plays an 
important role in the metabolism of tacrolimus, the major primary metabolite being 13-O-
demethyltacrolimus (Sattler et al., 1992; Karanam et al., 1994; Shiraga et al., 1994). It was, however, 
suggested that members of the CYP3A protein family other than CYP3A4 might be involved in the 
13-O demethylation of tacrolimus (Sattler et al., 1992). More recently, Bader et al. (Bader et al., 2000) 
established that tacrolimus is indeed metabolized by CYP3A5, but no detailed kinetic data were 
presented. 
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Using cDNA expressed P450 enzymes we could show that tacrolimus is indeed predominantly 
metabolized by members of the CYP3A subfamily to 13-O-demethyltacrolimus. The metabolites 
13,15-O-demethyltacrolimus and 13,31-O-demethyltacrolimus were also detected, but their amounts 
were 10-20 times lower than the corresponding levels of 13-0-demethyltacrolimus. Recombinant 
CYP3A5 metabolized tacrolimus with an affinity comparable to that of CYP3A4, but with a catalytic 
efficiency (Vmax/Km) that was 64% higher than that of CYP3A4, which makes tacrolimus a more 
specific substrate for CYP3A5 than CYP3A4. This further supports the growing recognition that the 
specific activities of CYP3A4 and CYP3A5 are comparable for certain substrates including 
ethylmorphine, lidocaine, testosterone and alfentanil (Gillam et al., 1995; Huang et al., 2004; Kamdem 
et al., 2004; Klees et al., 2005).  
The Km values observed for recombinant CYP3A4 (1.5 µmol/L) and CYP3A5 (1.4 µmol/L) were 
similar to the Km values obtained for the transformation of tacrolimus to 13-0-demethyltacrolimus in a 
bank of 15 human liver microsomes (median: 0.74 µmol/L; range: 0.38 to 1.20 µmol/L). Using the 
kinetic constants derived from the recombinant enzyme experiments and the concentrations of 
CYP3A4 and CYP3A5 protein in the respective microsomes, we were able to estimate the 
contribution of CYP3A5 to the transformation of tacrolimus in each microsomal preparation. The 
contribution of CYP3A5 to the 13-O-demethylation of tacrolimus in human liver microsomes varied 
from 1.5% to 40% and it was especially strong in livers with low CYP3A4, whereas it was lower in 
those with high CYP3A4 and in the three CYP3A5 “low expressers”. These findings support the 
observations that CYP3A5 is an important source of CYP3A interindividual variability, when 
CYP3A5 content represents a significant fraction of the total hepatic CYP3A pool (Huang et al., 2004; 
Kamdem et al., 2004; Yamaori et al., 2004). Conversely, the share of CYP3A5 in tacrolimus 
metabolism undergoes “dilution” in individuals with high CYP3A4 expression. In other words, the 
relative contribution of CYP3A5 strongly depends on the concomitant expression level of CYP3A4. 
The predominant role of CYP3A isoforms in the 13-O-demethylation of tacrolimus is in agreement 
with the good correlation observed between tacrolimus 13-O-demethylation activity and 6ß-
hydroxylation of testosterone in the liver samples investigated. The latter parameter is widely used as a 
marker of CYP3A activity (Yuan et al., 2002; Kamdem et al., 2004). 
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In our experiments , the average predicted tacrolimus pharmacokinetic clearances in CYP3A5 low 
expressers (3.57 ml/min/kg) and CYP3A5 high expressers (8.60 ml/min/kg) were in general in the 
same range as in vivo (0.68 – 6 ml/min/kg) (Christians et al., 2002). Clearance values >6 ml/min/kg 
observed in some liver samples may have been caused by the high CYP3A expression. 
Taken together, our results explain, at least in part, the recently reported positive association between 
CYP3A5 genotype and tacrolimus dosage (Macphee et al., 2002; Hesselink et al., 2003; Thervet et al., 
2003; Zheng et al., 2003; Haufroid et al., 2004; Zheng et al., 2004; Macphee et al., 2005; Thervet et 
al., 2005). Furthermore, our data offer an explanation for the substantial variability in tacrolimus 
dosage independent of CYP3A5 genotype, i.e. that observed within the groups of „high“ and „low“ 
CYP3A5 expressers (Haufroid et al., 2004). It is likely that a part of this variability is brought about 
by genotype-independent differences in CYP3A5 expression. Indeed, CYP3A5 expression varied two-
fold (range 6.9 to 14 pmol/mg) among the 12 “high expresser” livers. We speculate that an even 
bigger variability in tacrolimus maintenance dose is caused by differences in CYP3A4 expression. For 
comparison, the expression of this CYP3A isozyme varied 11-fold (27-300 pmol/mg) within the same 
set of 12 samples. Further variability may be due to differential inhibition or induction by exogenous 
substances (Gibbs et al., 1999; Khan et al., 2002; Burk et al., 2004) and due to the expression of 
CYP3A5 and CYP3A4 in the small intestine (Tsuchiya et al., 2004). This is particularly important for 
corticosteroids, since these compounds are often used concomitantly with tacrolimus after organ 
transplantation, and they are substrates, inducers, and inhibitors of CYP3A (Christians et al., 2002).  
Besides CYP3A, tacrolimus is a substrate for the P-glycoprotein encoded by the MDR1 gene and the 
trough concentration of tacrolimus is indeed affected by the intestinal expression level of MDR-1 
during the first week after transplantation. Subsequently, it is mostly hepatic metabolism that 
contributes to the clearance of tacrolimus (Goto et al., 2004). A polymorphism in the MDR1 has been 
associated with tacrolimus clearance (Macphee et al., 2002; Zheng et al., 2004) although these 
findings have not been confirmed by other investigators (Hesselink et al., 2003; Haufroid et al., 2004; 
Tsuchiya et al., 2004). Interestingly, MDR1 and CYP3A5 (as well as CYP3A4) share transcriptional 
activators such as pregnane X receptor (PXR) (Geick et al., 2001; Burk et al., 2004). This latter 
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mechanism may explain the intriguing findings by Goto et al., who described an association between a 
MDR1 polymorphism and CYP3A4 expression (Goto et al., 2004).  
Tacrolimus emerges as another clinically-relevant substrate of CYP3A5. Previously, Katz et al. (Katz 
et al., 2004) found that in vivo drug disposition of ABT-773, a ketolide antibiotic that is a substrate for 
both CYP3A and P-glycoprotein, depends on the CYP3A5, but not on the MDR-1 genotype. CYP3A5 
expressers showed a higher metabolism of lovastatin, simvastatin and atorvastatin (Kivisto et al., 
2001), whereas, no association was found between the polymorphism and efficacy of statins which are 
not metabolized by CYP3A5 (fluvastatin, pravastatin). 
What are the implications of our findings for the currently discussed (Park et al., 2003), prospect of 
CYP3A5 genotyping in patients treated with tacrolimus? Certainly, CYP3A5 genotyping will not 
eliminate the need to monitor tacrolimus blood concentrations, since CYP3A4 also contributes to its 
metabolism and the expression levels of both CYP3A4 and CYP3A5 (Burk et al., 2004) undergo 
strong modulation by non-genetic (environmental) factors. However, a CYP3A5 genotype-based 
adjusted initial dosing regimen for tacrolimus, may allow a more rapid and efficient attainment of 
therapeutic blood levels in the early postoperative period. Indeed, CYP3A5 high expressers had lower 
mean tacrolimus concentrations during the first week after transplantation and rejection occurred 
earlier in these patients (MacPhee et al., 2004). Prospective studies are now needed to validate this 
hypothesis. 
 
5.4  Contribution of CYP3A4, CYP3A5, CYP3A7 and CYP1A2 to the 
hepatic production of aflatoxin B1-8,9-epoxide 
The primary steps of detoxification and carcinogenic activation of AFB1 have been reported to be 
catalyzed by CYP3A4, CYP3A5, CYP3A7, and CYP1A2. All these enzymes exhibit substantial inter-
individual expression variability, which could affect the ratio between the AFB1 detoxification and 
activation. This ratio is likely an important determinant of the individual risk to AFB1-induced HCC. 
Our study constitutes a first investigation of the metabolism of AFB1 by these P450s at concentrations 
encountered in the liver tissue of exposed individuals, i.e. at around 0.1 µM (Wild et al., 1992; 
Gallagher et al., 1996; Doi et al., 2002).For this purpose, the metabolism of AFB1 was assessed at 
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concentrations easily measurable with HPLC and adjusted using a hepatic abundance model. This 
model takes into consideration the specific activities of the individual P450s and their hepatic 
expression levels, which had to be determined to start with. The AFB1 metabolite spectra and, where 
available, the kinetic parameters were in agreement with previous reports (Gillam et al., 1995; 
Gallagher et al., 1996; Ueng et al., 1997; Wang et al., 1998). AFBO was the exclusive AFB1 product 
catalyzed by the recombinant CYP3A5, but it was also catalyzed by CYP3A4, CYP3A7, and 
CYP1A2. AFBO is a mix of the genotoxic AFB1-8,9-exo-epoxide and the less toxic stereoisomer 
AFB1-endo-8,9-epoxide, but it is a fair measure of the AFB1 carcinogenic activation (Ueng et al., 
1995). AFQ1, the major detoxification product, was catalyzed by CYP3A4 and CYP3A7, whereas 
AFM1 was specific for CYP1A2. The extent of CYP3A4 variability in HLMs was smaller than in 
some previous studies, but it was in the same range as that recently reported by Sim et al. (Sim et al., 
2005). It has been suggested that the variability in the expression of CYP3A4 may have been 
overestimated in earlier studies, due to tissue collection artefacts (Floyd et al., 2003). The expression 
of CYP3A5 was bimodal, as reported previously (Hustert et al., 2001; Kuehl et al., 2001). To allow for 
a first estimate of the contribution of CYP3A7 to AFB1 metabolism, we used CYP3A7 expression 
levels measured in human livers with a recently developed, specific CYP3A7 antibody (Sim et al., 
2005).  
For the epidemiologically-relevant AFB1 concentration of 0.1 µM, our data predict a substantial inter-
individual variability of the toxin’s disposition. The share of AFB1 converted to the carcinogenic 
AFBO varies between 5% and 37% even in this relatively small set of HLMs. Correspondingly the 
rate widely (from 19:1 to 1.7:1) varies between AFBO and AFQ1, the primary detoxification product 
of AFB1. The hepatic abundance model predicts that a majority of both AFBO and AFQ1 is catalyzed 
by CYP3A4. This is supported by the high correlation coefficients between the HLM expression levels 
of CYP3A4 and Vmax values of, respectively, AFBO and AFQ1 production. It is also in agreement 
with the high correlation between Vmax values of AFBO and AFQ1 formations measured in HLMs, 
when taking into account the similarity of AFBO and AFQ1 kinetics in recombinant CYP3A4 and 
HLMs.  
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Although recombinant CYP3A7 also generates AFQ1, its extent is negligible in most individuals in 
comparison to CYP3A4, since they express only traces of CYP3A7 (Sim et al., 2005). In CYP3A7 
high expressers, which account for approximately 15% of Caucasians (Sim et al., 2005), this P450 
may contribute on average almost a quarter of AFQ1 production. This estimate is based on CYP3A7 
accounting for almost a quarter of the total CYP3A in CYP3A7 high expressers (Sim et al., 2005), 
combined with similar specific AFB1 clearances of CYP3A4 and CYP3A7 towards AFQ1. The 
frequencies of the CYP3A7 polymorphism in populations exposed to high AFB1 concentrations such 
as Asians and Africans are currently unknown.  
A dominant role of CYP3A4 in AFBO production is in agreement with the findings of Doi and 
colleagues, who detected a correlation approaching statistical significance between CYP3A4 
expression and AFB1-DNA, adduct levels in a panel of adult human livers (Doi et al., 2002). In 
addition to CYP3A4, AFBO production is contributed to by CYP3A5, CYP3A7, and CYP1A2, which 
may affect the share of AFB1 converted to AFBO. The contribution of CYP3A7 in CYP3A7 high 
expressers (Sim et al., 2005) is estimated to be between 5% and 7%, whereas that of CYP1A2 is 
between 1% and 5%. CYP3A5 may contribute up to 15.3% of AFBO in CYP3A5 high expressers. 
This value is still relatively modest in comparison with CYP3A4 (79-95%) and it is consistent with the 
low value of the correlation coefficient between the CYP3A5 protein expression level and Vmax of 
AFBO production in the HLMs investigated. On the other side, we found a significant, inverse 
correlation between the contribution of CYP3A5 to the hepatic AFBO production, and the expression 
of the CYP3A4 protein. This means that the relative contribution of CYP3A5 to AFBO production is 
highly dependent on the concomitant expression of CYP3A4. This is in agreement with the recent 
observation of AFB1-albumin adducts blood plasma levels increased especially strongly in AFB1-
exposed CYP3A5 high expressers with low concomitant CYP3A4 expression (Wojnowski et al., 
2004). Similar relationships have been reported for several other substrates common to CYP3A4 and 
CYP3A5, with the effect of the CYP3A5 polymorphism especially pronounced against a background 
of low CYP3A4 expression (Huang et al., 2004; Kamdem et al., 2004; Kamdem et al., 2005).In 
summary, these findings indicate that, following CYP3A4, CYP3A5 expression status is the second-
most important determinant of the carcinogenic AFB1 activation to AFBO. The clinical importance of 
 77
 
Discussion 
the CYP3A5 effect on AFB1 metabolism will be ultimately determined by genotyping HCC patients 
from areas of high AFB1 exposure. 
We detected in our microsomal incubations no AFM1, which is an AFB1 metabolite specific for 
CYP1A2. Usually considered a detoxification product, AFM1 can be converted, e.g. by cultured liver 
cells, to the genotoxic AFM-8,9-epoxide (Loveland et al., 1988; Bujons et al., 1995; Neal et al., 1998). 
Such a conversion could be responsible for the absence of AFM1 from our incubations of HLMs with 
AFB1. Alternatively, the production of AFM1 may have been simply too low to be detected. In 
agreements with this latter interpretation, the production of AFM1 by HLMs was a magnitude smaller 
that that of AFQ1 in the available reports on hepatic AFM1 production (Ramsdell and Eaton, 1990; 
Ramsdell et al., 1991). Likewise, median AFM1 concentrations in urine and feces of AFB1-exposed 
Chinese individuals accounted, respectively, for 1/60th and 1/260th of the corresponding AFQ1 values 
(Mykkanen et al., 2005). In the same study, urinary excretion of AFQ1 (but not that of AFM1) 
correlated significantly with the excretion of the AFB1-N7-guanine adduct, which is considered to be 
the best predictor of hepatocellular carcinoma risk (Groopman et al., 1992; Qian et al., 1994; 
Groopman et al., 1996). Furthermore, Doi and colleagues (Doi et al., 2002) detected no correlation 
between CYP1A2 expression level and AFB1-DNA adducts in the same panel of microsomes from 10 
human livers in which they reported a correlation approaching statistical significance between these 
adducts and CYP3A4 expression. In conclusion, all these data suggest that the disposition of AFB1 to 
AFM1 in HLMs may be negligible.  
Similarly negligible may be the contribution of CYP1A2 to the formation of AFBO. Our conclusion 
that CYP3A4 is responsible for the majority of AFBO formation in human livers is in agreement with 
expectations from several studies with purified or recombinant P450 (Shimada and Guengerich, 1989; 
Forrester et al., 1990; Guengerich and Kim, 1990; Raney et al., 1992a; Raney et al., 1992b; Raney et 
al., 1992c; Gillam et al., 1995). It is in opposition to the only work which assessed AFB1 metabolism 
in microsomes from human livers (Gallagher et al., 1996). These authors predicted that, at AFB1 
concentrations encountered in vivo, over 99% of the hepatic AFBO production would be contributed 
by CYP1A2. However, the critically important hepatic expression levels of CYP1A2 and CYP3A4 
were not considered in the calculation. The postulated dominant role of CYP1A2 in AFBO production 
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was also not supported by: 1) Vmax of AFBO production, which was highest in the liver with the 
highest CYP3A4 expression and not in the liver with the highest CYP1A2 expression, as would be 
expected (Table2 in (Gallagher et al., 1996) and 2) the finding that only 20-46% of AFBO production 
was inhibited by the specific CYP1A2 inhibitor furafylline (compare Tables 1 and 2 in (Gallagher et 
al., 1996)).  
Could our findings have any immediate implications for public health decisions in areas with high 
prevalence of AFB1-associated HCC? Preventive measures such as vaccination or chemoprotection 
are expected to reduce the burden of HCC especially effectively if they are applied to individuals at 
particularly high risk. Since all AFB1 metabolizing enzymes are expressed in the liver at individually 
variable levels, targeted chemoprotection by P450 inhibition represents a valid hypothesis (Kensler et 
al., 2003). Our results argue against targeting any preventive measures specifically to CYP3A5, 
CYP3A7, or CYP1A2 high expressers. Considering the prominent contribution of CYP3A4 to AFBO 
formation, much more effective should be the inhibition of CYP3A4 in individuals with particularly 
high hepatic levels of this P450. However, this would require genetic or phenotypic CYP3A4 activity 
markers, the development of which has proven difficult. More practical would be the reduction of 
CYP3A4 expression by avoiding pharmacological and dietary CYP3A4 inducers. These substances 
can sometimes enhance the turnover of CYP3A4 drug substrates to an extent where their effectiveness 
is abolished (Lucey et al., 1990) and they likely increase AFBO levels in individuals exposed to 
AFB1. Preventing CYP3A4 induction would have the added benefit of a similar effect on CYP3A5 
and CYP3A7 in the respective high expressors of these P450. Indeed, all three CYP3A genes exhibit 
overlaps in the spectra of inducers, due to similarities in their transcription regulation (Burk et al., 
2002; Burk et al., 2004).  
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6  CONCLUDING REMARKS 
Three substrates (Testosterone, Aflatoxin B1 and Tacrolimus) have been used to investigate the impact 
of CYP3A5 genetic polymorphism on biotransformation. The main conclusions from this investigation 
are: 
1. Under similar expression and incubation conditions, CYP3A4 and CYP3A5 exhibit similar 
specific activities and are similarly dependent on cytochrome b5. 
2. On average, the contribution of CYP3A5 to 6ß-hydroxylation of testosterone in Caucasian 
livers is limited (3%), due to the much lower expression levels of CYP3A5 in comparison to 
CYP3A4. However, it may approach 5-54% in CYP3A5 high expressers with concomitant 
low expression of CYP3A4. 
3. CYP3A5 is an important source of variability in the hepatic clearance of tacrolimus, thus 
explaining the positive association observed between CYP3A5 genotype and tacrolimus 
dosage. The importance of CYP3A5 for tacrolimus clearance is also dependent on the 
concomitant CYP3A4 activity. 
4. CYP3A4 contributed a majority of AFBO and AFQ1 and its expression level was the most 
important determinant of the AFB1 disposition towards these primary metabolites. CYP3A5, 
which exclusively produced AFBO, was the second-most important enzyme activating AFB1 
to AFBO, followed by CYP3A7 and CYP1A2. 
Altogether, these findings suggest that CYP3A5 is an important source of CYP3A interindividual 
variability, when CYP3A5 content represents a significant fraction of the total hepatic CYP3A pool. 
 
80 
Future Perspectives 
 
7  FUTURE PERSPECTIVES 
Among patients differences in drug responses are common and often lead to challenges in optimizing 
a dosage regimen for an individual patient. Such variability in drug response is multifactorial, 
including environmental, disease state and genetic factors that affect drug disposition. 
Pharmacogenetics is one of the fields of clinical pharmacology, which studies how genetic factors 
influence drug response. Today, the relationship between dosage requirements and pharmacogenetic 
polymorphisms in drug metabolizing enzymes are best  substantiated  for cytochromes such as 
CYP2D6 (antidepressants, antipsychotics, analgesics) (Kirchheiner et al., 2004; Lotsch et al., 2004; 
Ingelman-Sundberg, 2005), CYP2C9 (warfarine, antidiabetics) (Kirchheiner and Brockmoller, 2005)), 
CYP2C19 (diazepam, proton pump inhibitors) (Goldstein, 2001; Desta et al., 2002; Wilkinson, 2005) 
and CYP2B6 (efavirenz) (Haas et al., 2004; Rotger et al., 2005).  
CYP3A plays a dominant role in the metabolic elimination of more xeno- and endobiotics than any 
other biotransformation enzyme and the pharmacogenetic determinants of CYP3A interindividual 
differences have been identified. The most frequent ones are found in CYP3A5 and CYP3A7, which 
are represented by CYP3A5*1 and the newly identified CYP3A7*2 genetic variants, respectively. 
CYP3A4*1B, the only common CYP3A4 variant does not appear to substantially affect the CYP3A4 
function  in vitro and in vivo; and is in linkage disequilibrium with CYP3A5*1 allele. Whereas the 
clinical relevance of CYP3A7 and CYP3A43 polymorphisms remains to be assessed, the polymorphic 
expression of CYP3A5 provides a possible explanation for the lower CYP3A-mediated metabolism 
reported in some individuals when compared to others. However, the penetrance of the CYP3A5 
polymorphism is likely to be compromised by the concomitant expression of CYP3A4, although its 
relevance may be higher in organs devoid of CYP3A4 expression, such as kidney. Therefore, these 
markers will unlikely lead to any clinical application as long as there are no markers predictive of 
CYP3A4 expression. As mentioned above, the expressivity of the CYP3A5 polymorphism in relation 
to drug metabolism strongly depends on the concomitant expression of CYP3A4, and also this will 
likely be the case for the CYP3A7 polymorphism and CYP3A4. Possible exceptions to the rule could 
be drugs predominantly metabolized by either CYP3A7 or CYP3A5, but not by CYP3A4. At present, 
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the most promising candidate for such a drug is tacrolimus, where almost half of the dose variability 
can be explained via the CYP3A5 polymorphism status. The expressivity of the CYP3A5 
polymorphism could also be sufficient in the absence of substrate specificity, e.g. in the kidney, which 
expresses only very low levels of CYP3A4 and CYP3A7.  Nevertheless, the emerging associations 
with CYP3A5*1 alleles are unlikely to lead to routine clinical genotyping of this variant in the near 
future. This assessment is first of all based on the clinical application of some other polymorphisms in 
drug metabolizing enzymes, which have been known for a long time while this knowledge has not 
been translated into clinical applications. This has been mostly due to the lack of clinical studies 
demonstrating the clinical value of genotyping using the criteria of evidence-based medicine. This 
situation may change dramatically, depending on the results of several ongoing large prospective 
studies, e.g. on the anticoagulant warfarine and the CYP2C9 polymorphism, but this will take several 
years. The development and validation of markers predictive of CYP3A expression is likely to take 
even longer, especially if we ultimately fail to develop markers predictive for CYP3A4. In this case, it 
may still be possible to reduce drug interactions involving CYP3A by pharmacological means. 
Cyclosporine has been administered in some countries together with CYP3A inhibitors, such as 
ketoconazole or diltiazem. This procedure has allowed for a reduction of this drug’s dose by up to 
85% without any effects on efficacy or toxicity (Martin et al., 1999). Similar strategies could be 
applied to other drugs that are metabolized by CYP3A and have a narrow therapeutic index. 
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8  SUMMARY 
Enzymes of the cytochrome P450 (CYP) subfamily 3A comprise the largest portion of the liver and 
small intestinal CYP protein and they are involved in the metabolism of 45-60% of all currently used 
drugs. In addition to drugs, CYP3A isozymes metabolize a variety of other compounds including 
steroid hormones, toxins and carcinogens. It is also well known that the hepatic expression and 
activity of CYP3A isozymes varies from individual to individual. Unlike CYP3A4, the homologous 
enzyme CYP3A5 is polymorphically expressed. Several genetic variants, of which CYP3A5*3 is the 
only one found in all ethnic groups, can reduce the expression of CYP3A5 to less than 1/1000 of that 
found in carriers of the wild type allele (CYP3A5*1). 
To investigate the significance of CYP3A5 genetic polymorphism in the metabolism of drugs and 
carcinogens, we assessed the relative contribution of CYP3A5 to the 6ß-hydroxylation of testosterone 
(steroid hormone), to the 13-O demethylation of tacrolimus (an immunosuppressive drug), and to the 
8,9-epoxidation of AFB1 (carcinogen) using cDNA-expressed enzymes and a bank of human liver 
microsomes derived from low and high CYP3A5 expressers. 
In our experiments, under similar expression and incubation conditions, CYP3A4 and CYP3A5 
exhibit similar specific activities toward testosterone. A co-expression of cytochrome b5 (b5) has a 
much stronger effect on the CYP3A4 activity than its addition to the incubation mixture. For 6ß-
hydroxytestoterone formation the calculated Km and Vmax values for CYP3A4 and CYP3A5 cDNA-
expressed microsomes were 129 µM and 14.5 pmol/pmol CYP/min, 114 µM and 13.1 pmol/pmol 
CYP/min, respectively. With human liver microsomes (HLM), the CYP3A5 low expressers had a 
mean testosterone 6ß-hydroxylation Vmax value of 3798 pmol/mg/min, compared with 2976 
pmol/mg/min in CYP3A5 high expressers (statistically not a significant difference). The CYP3A5 
contribution to 6ß-hydroxylation of testosterone accounted on average for 30% in CYP3A5 high 
expresser livers. 
Recombinant CYP3A5 metabolized tacrolimus with an affinity comparable to that of CYP3A4, but 
with an intrinsic clearance (Vmax/Km) that was 64% higher than that of CYP3A4. The calculated Km 
and Vmax values (13-O-demethyltacrolimus formation) for CYP3A4 versus CYP3A5 cDNA-expressed 
microsomes were 1.5 µM and 0.72 pmol/pmol CYP/min, 1.4 µM versus 1.1 pmol/pmol CYP/min, 
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respectively. With HLM, the CYP3A5 low expressers had a mean tacrolimus 13-O demethylation Vmax 
value of 285 pmol/mg/min, compared with 981 pmol/mg/min in CYP3A5 high expressers. The 
contribution of CYP3A5 to 13-O-demethylation of tacrolimus in human liver microsomes varied from 
1.5% to 40% and was particularly strong in livers with low CYP3A4, whereas it was lower in those 
with high CYP3A4. 
The calculated Km and Vmax values (AFB1-8,9-epoxide formation) for CYP3A4 versus CYP3A5 
cDNA-expressed microsomes were 130 µM and 1.64 pmol/pmol CYP/min, 302 µM versus 1.2 
pmol/pmol CYP/min, respectively. With HLM, the CYP3A5 low expressers had a mean AFB1-8,9-
epoxidation Vmax value of 545 pmol/mg/min, compared with 873 pmol/mg/min in CYP3A5 high 
expressers. The relative contribution of CYP3A5 to AFBO formation strongly depended on the 
expression of CYP3A4 and it was as high as 15% in a CYP3A5 high expresser with the lowest amount 
of CYP3A4 protein of all livers. 
Altogether, these findings demonstrate that CYP3A5 is an important source of CYP3A interindividual 
variability, when CYP3A5 represents a significant fraction of the total hepatic CYP3A pool. Among 
the CYP3A substrates analyzed in the present work, the impact of CYP3A5 was highest for the 
immunosuppressant tacrolimus.  
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